Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease.
paper
Cited
Public
Unavailable
- Authors
- Donnelly, Kerry L; Smith, Coleman I; Schwarzenberg, Sarah J; Jessurun, Jose; Boldt, Mark D; Parks, Elizabeth J
- Year
- 2005
- Journal
- The Journal of clinical investigation
- PMID
- 15864352
- DOI
- 10.1172/JCI23621
- PMCID
- PMC1087172
Nonalcoholic fatty liver disease (NAFLD) is characterized by the accumulation of excess liver triacylglycerol (TAG), inflammation, and liver damage. The goal of the present study was to directly quantify the biological sources of hepatic and plasma lipoprotein TAG in NAFLD. Patients (5 male and 4 female; 44 +/- 10 years of age) scheduled for a medically indicated liver biopsy were infused with and orally fed stable isotopes for 4 days to label and track serum nonesterified fatty acids (NEFAs), dietary fatty acids, and those derived from the de novo lipogenesis (DNL) pathway, present in liver tissue and lipoprotein TAG. Hepatic and lipoprotein TAG fatty acids were analyzed by gas chromatography/mass spectrometry. NAFLD patients were obese, with fasting hypertriglyceridemia and hyperinsulinemia. Of the TAG accounted for in liver, 59.0% +/- 9.9% of TAG arose from NEFAs; 26.1% +/- 6.7%, from DNL; and 14.9% +/- 7.0%, from the diet. The pattern of labeling in VLDL was similar to that in liver, and throughout the 4 days of labeling, the liver demonstrated reciprocal use of adipose and dietary fatty acids. DNL was elevated in the fasting state and demonstrated no diurnal variation. These quantitative metabolic data document that both elevated peripheral fatty acids and DNL contribute to the accumulation of hepatic and lipoprotein fat in NAFLD.
No figures extracted from this document.
No chunks — full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Activation of mitophagy antagonizes high uric acid-induced hepatic lipid accumulation. | Chen J et al. | — | 2026 | → |
| A Self-Assembled Irinotecan Nanomedicine Abrogates Steatohepatitis-Induced Liver Metastasis and Potentiates Antitumor Efficacy against Colorectal Cancer. | Xiang M et al. | — | 2026 | → |
| Bidirectional regulation of free fatty acid receptors and non-alcoholic fatty liver disease. | Lin Y et al. | — | 2026 | → |
| Cannabidiolic acid as a modulator of lipid metabolism in the liver of rats with metabolic-associated steatotic liver disease. | Kurzyna PF et al. | — | 2026 | → |
| DDR2 ameliorates nonalcoholic hepatic steatosis by activating the AMPK/ACC pathway. | Guo M et al. | — | 2026 | → |
| Dietary arginine modulates egg production and mTOR signalling pathway gene expression in adult Japanese quail (<i>Coturnix japonica</i>). | Gashew M et al. | — | 2026 | → |
| Dysregulation of the AMPK-SREBP1-FASN axis in MASLD: driving a vicious cycle of lipotoxicity and metabolic-immune crosstalk. | Zhao Q et al. | — | 2026 | → |
| Effect of free fatty acids on TGF-β1 mediated fibrogenesis in hepatic stellate cells. | De Nardo W et al. | — | 2026 | → |
| Effects of Acute Iso- and Hypocaloric Carbohydrate Restriction on Liver Fat and Glucose and Lipid Metabolism. | London A et al. | — | 2026 | → |
| Gut Mycobiota-Associated Tryptophan Catabolites Protect Against Metabolic Dysfunction-Associated Steatotic Liver Disease. | Qiao S et al. | — | 2026 | → |
| Hepatocyte SAMHD1 Deficiency Attenuates Hepatic Steatosis via Suppression of SREBP Activation in a Mouse Model of Metabolic-Associated Steatotic Liver Disease. | Yin G et al. | — | 2026 | → |
| Human MASLD is a diurnal disease driven by multisystem insulin resistance and reduced insulin availability at night. | Marjot T et al. | — | 2026 | → |
| Hypercohin A alleviates hepatic steatosis via the mammalian target of rapamycin (mTOR)-dependent suppression of de novo lipogenesis and ferroptosis. | Cao F et al. | — | 2026 | → |
| Hyperinsulinemia, an overlooked clue and potential way forward in metabolic dysfunction-associated steatotic liver disease. | Harrison SA et al. | — | 2026 | → |
| Hyperoside modulates bile acid and fatty acid metabolism, presenting a potentially promising treatment for non-alcoholic fatty liver disease. | Wang S et al. | — | 2026 | → |
| Impaired hepatic metabolism in Hereditary Fructose Intolerance confers fructose-independent risk for steatosis and hypertriglyceridemia. | Fulham MA et al. | — | 2026 | → |
| Improving Non-alcoholic Fatty Liver Disease Treatment in High-fat Diet Fed Mice with Fisetin and Hydroxychloroquine: The Cooperative Pathways for Improved Metabolic Health. | Sattari M et al. | — | 2026 | → |
| Incretin and Glucagon Signalling in MASLD and MASH: Integrating Metabolic Pathways With Disease Progression. | Tsakiridis EE et al. | — | 2026 | → |
| Inflammation promotes hepatic but not adipose tissue DGAT2 expression and triglyceride synthesis in MAFLD mice. | Vairappan B et al. | — | 2026 | → |
| Integrin β3 Orchestrates Hepatic Steatosis via a Novel CD36-Dependent Lipid Uptake Complex. | Zhang Y et al. | — | 2026 | → |
| LC-MS measurement of triglyceride hydrolysis: Application in studies of Patatin-like phospholipase domain-containing protein 3 activity. | Chen X et al. | — | 2026 | → |
| Lipid Droplet Dynamics in Alcoholic Steatohepatitis. | Omar DY et al. | — | 2026 | → |
| Mitochondrial retrograde signal through GCN5L1 transition-mediated PPARγ stabilization promotes MASLD development. | Zhang J et al. | — | 2026 | → |
| Modeling Glucose, Insulin, C-Peptide, and Lactate Interplay in Adolescents During an Oral Glucose Tolerance Test. | Bonet J et al. | — | 2026 | → |
| Mycobiome dysbiosis and genetic predisposition to elevated IL-17A contribute to fibrosis in MASLD. | Thielemann N et al. | — | 2026 | → |
| Myeloid AEG-1/MTDH drives inflammation and hepatocellular dysfunction in diet-induced steatohepatitis. | Raha S et al. | — | 2026 | → |
| Nanotechnology-driven biomaterials for chronic liver diseases: Stage-specific strategies for advanced theranostics. | Cai Y et al. | — | 2026 | → |
| Nutrigenomics of fat-soluble vitamins and micronutrients in hepatocyte lipotoxicity and MASLD. | Migni A et al. | — | 2026 | → |
| Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Literature Review on Pathophysiology and Treatment. | Romanos M et al. | — | 2026 | → |
| Oxytocin Receptor Polymorphism rs53576 Is Linked to Habitual Alcohol and Sucrose Intake, as well as Liver Steatosis, in a General Japanese Population Cohort. | Goto H et al. | — | 2026 | → |
| Paulobutalipin, a Lipid Accumulation Inhibitor from a <i>Streptomyces sp.</i> | Huynh TH et al. | — | 2026 | → |
| PDIA6 as a novel pharmacological target for metabolic dysfunction-associated steatohepatitis via alleviating endoplasmic reticulum stress. | Hu H et al. | — | 2026 | → |
| Pevonedistat targeting NEDDylation activating enzyme for human diseases: Underlying mechanisms, clinical studies, and future directions. | Fu DJ et al. | — | 2026 | → |
| Physical exercise in liver diseases. | Zhang Y et al. | — | 2026 | → |
| Post-translational modifications of selective autophagy receptors: orchestrating cellular homeostasis, disease pathogenesis, and therapeutic opportunities. | Zhu W et al. | — | 2026 | → |
| Pregnane X receptor antagonist MI-891 reduces hepatic triglycerides in PXR-CAR-CYP3A4/3A7-humanized mice. | Dohnalová K et al. | — | 2026 | → |
| Promoter demethylation and protein O-GlcNAcylation-mediated enhancement of fatty acid synthase contributes to hepatic steatosis and inflammation in MASLD. | Lin ZH et al. | — | 2026 | → |
| Protein lactylation in metabolic dysfunction-associated steatotic liver disease: a mechanistic review. | Chen H et al. | — | 2026 | → |
| Therapeutic targets for metabolic dysfunction-associated steatohepatitis: a personalized approach to disease management. | Rinella ME et al. | — | 2026 | → |
| The Role of Kupffer Cells and Liver Macrophages in the Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease. | Tsomidis I et al. | — | 2026 | → |
| AASLD Practice Statement on the evaluation and management of metabolic dysfunction-associated steatotic liver disease in children. | Xanthakos SA et al. | — | 2025 | → |
| AAV capsid prioritization in normal and steatotic human livers maintained by machine perfusion. | Kim JJ et al. | — | 2025 | → |
| Ablation of Hepatocyte Derived-FGL1 Does Not Aggravate Metabolic Dysfunction-Associated Steatotic Liver Disease. | Personnaz J et al. | — | 2025 | → |
| Abscisic acid improves non-alcoholic fatty liver disease in mice through the AMPK/NRF2/KEAP1 signaling axis. | Zhang L et al. | — | 2025 | → |
| Adipose microsomal triglyceride transfer protein deficiency protects against hepatic steatosis by upregulating PPARα activity. | Rajan S et al. | — | 2025 | → |
| Adipose Tissue Dysfunction and Metabolic Diseases: The Role of Vitamin D/Vitamin D Receptor Axis. | Cimini FA et al. | — | 2025 | → |
| Adiposity and Metabolic Indices in the Diagnosis and Histological Stage Association of Metabolic Dysfunction-Associated Steatotic Liver Disease. | Ibarra-Reynoso LDR et al. | — | 2025 | → |
| Advancing de novo lipogenesis: Genetic and metabolic insights. | Hartig SM et al. | — | 2025 | → |
| A hierarchical hepatic de novo lipogenesis substrate supply network utilizing pyruvate, acetate, and ketones. | Rauckhorst AJ et al. | — | 2025 | → |
| Albumin Reduces Hepatic Steatosis and Inflammation in High-Fat-Diet-Fed Mice. | Rennie C et al. | — | 2025 | → |
| Alterations in ether lipid metabolism in obesity revealed by systems genomics of multi-omics datasets. | Schooneveldt YL et al. | — | 2025 | → |
| A metabolome-derived score predicts metabolic dysfunction-associated steatohepatitis and mortality from liver disease. | Huang Q et al. | — | 2025 | → |
| A murine model of obesity with hyperinsulinemia and hepatic steatosis involving neurosecretory protein GL gene and a low-fat/medium-sucrose diet. | Narimatsu Y et al. | — | 2025 | → |
| Are glyphosate or glyphosate-based herbicides linked to metabolic dysfunction-associated steatotic liver disease (MASLD)? The weight of current evidence. | Riechelmann-Casarin L et al. | — | 2025 | → |
| Asiaticoside alleviated NAFLD by activating Nrf2 and inhibiting the NF-κB pathway. | Wei Y et al. | — | 2025 | → |
| Association between HOMA-IR and metabolic dysfunction-associated steatohepatitis in U.S. adults with MASLD. | Tang XX et al. | — | 2025 | → |
| Association of metabolic signatures of air pollution with MASLD: Observational and Mendelian randomization study. | Ran S et al. | — | 2025 | → |
| Association of weight-adjusted waist index with all-cause and cardiovascular mortality in patients with metabolic dysfunction-associated steatotic liver disease: a national population-based cohort study. | Zhang F et al. | — | 2025 | → |
| Autoimmune mechanisms and inflammation in obesity-associated type 2 diabetes, atherosclerosis, and non-alcoholic fatty liver disease. | Sun Y et al. | — | 2025 | → |
| Bile acid signaling in MASLD: From pathogenesis to therapeutic applications. | Simbrunner B et al. | — | 2025 | → |
| Can targeting de novo lipogenesis improve liver health? | Castro Cabezas M et al. | — | 2025 | → |
| Carbon tetrachloride does not promote hepatic fibrosis in ob/ob mice via downregulation of lipocalin-2 protein. | Shin HJ et al. | — | 2025 | → |
| Cardiovascular disease and metabolic dysfunction-associated steatotic liver disease: pathophysiology and diagnostic aspects. | Møller S et al. | — | 2025 | → |
| Cardiovascular Risk Reduction in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis. | Bernhard J et al. | — | 2025 | → |
| Causal Relationship Between Genetically Determined Free Fatty Acids and Nonalcoholic Fatty Liver Disease: A Mendelian Randomization Study. | Li K et al. | — | 2025 | → |
| Celastrol Improves Preference for a Fatty Acid, and Taste Bud and Systemic Inflammation in Diet-Induced Obese Mice. | Benmouna M et al. | — | 2025 | → |
| Changes After Leptin Administration in Partial Lipodystrophy and Factors Associated With Hepatic and Metabolic Response. | Akinci B et al. | — | 2025 | → |
| Chemogenetic activation of hepatic G<sub>12</sub> signaling ameliorates hepatic steatosis and obesity. | Arai K et al. | — | 2025 | → |
| Circulating glycerate predicts resilience to fructose-induced hepatic steatosis. | Ramirez CB et al. | — | 2025 | → |
| Close multilevel links between metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus. | Holleboom AG et al. | — | 2025 | → |
| Comparison of the effects of pemafibrate and omega-3 fatty acid ethyl on fatty liver index in patients with dyslipidemia treated with statin: a sub-analysis from the PROUD48 study. | Takeda Y et al. | — | 2025 | → |
| Comprehensive exploration of marine functional foods in modulation of metabolic syndromes: a 20-year review. | Amanat M et al. | — | 2025 | → |
| Consensus guidelines for the diagnosis and management of metabolic dysfunction-associated steatotic liver disease in adult Asian Indians with type 2 diabetes. | Misra A et al. | — | 2025 | → |
| Cosupplementation with DHA and medium-chain triglycerides ameliorates NAFLD and reduces amyloid-β accumulation by modulating hepatic lipid metabolism in APP/PS1 mice. | Zhang D et al. | — | 2025 | → |
| Creatine kinase B regulates glycolysis and de novo lipogenesis pathways to control lipid accumulation during adipogenesis. | Renzi G et al. | — | 2025 | → |
| Daily glucose variability is associated with intrahepatic fat content, β cell sensitivity, and biomarkers of glycolysis in youth with obesity. | Barbieri E et al. | — | 2025 | → |
| Deuterium MRS for In Vivo Measurement of Lipogenesis in the Liver. | Gursan A et al. | — | 2025 | → |
| Dietary fibre-adapted gut microbiome clears dietary fructose and reverses hepatic steatosis. | Jung S et al. | — | 2025 | → |
| Drug Pipeline for MASLD: What Can Be Learned from the Successful Story of Resmetirom. | Knezović E et al. | — | 2025 | → |
| Dysglycemia and liver lipid content determine the relationship of insulin resistance with hepatic OXPHOS capacity in obesity. | Kahl S et al. | — | 2025 | → |
| Dysregulated bile acid metabolism drives lipid peroxidation and ferroptosis in NAFLD: therapeutic potential for traditional Chinese medicine. | Liu J et al. | — | 2025 | → |
| Early stage of metabolic dysfunction associated steatotic liver disease disrupts circadian rhythm and induces neuroinflammation in rats. | Graindorge PH et al. | — | 2025 | → |
| Effects of Diet and Exercise on Mitochondrial Health in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Role of Ceramides. | McCaffrey JM et al. | — | 2025 | → |
| Effects of Selected Food Additives on the Gut Microbiome and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). | Jarmakiewicz-Czaja S et al. | — | 2025 | → |
| Efficacy of fish oil supplementation on metabolic dysfunction-associated steatotic liver disease: a meta-analysis. | Zhou L et al. | — | 2025 | → |
| Elevation of hepatic de novo lipogenesis in mice with overnutrition is dependent on multiple substrates. | Strober JW et al. | — | 2025 | → |
| Endoplasmic reticulum stress at the forefront of fatty liver diseases and cancer. | Karin M et al. | — | 2025 | → |
| Enpp1 ameliorates MAFLD by regulating hepatocyte lipid metabolism through the AMPK/PPARα signaling pathway. | Liu X et al. | — | 2025 | → |
| Epigenetic Changes Associated With Obesity-related Metabolic Comorbidities. | Sandovici I et al. | — | 2025 | → |
| Establishing the Role of Liver Fatty Acid-Binding Protein in Post-Golgi Very-Low-Density Lipoprotein Trafficking Using a Novel Fluorescence-Based Assay. | Winterfeldt K et al. | — | 2025 | → |
| Estimated sdLDL-C as a biomarker of hepatic steatosis severity in MASLD: a retrospective study. | Jiang S et al. | — | 2025 | → |
| Ethnic differences in metabolic and histologic features among White, Hispanic, Black and Asian patients with metabolic-associated Steatotic liver disease: A network meta-analysis. | Lin L et al. | — | 2025 | → |
| Exploring the interplay between metabolic dysfunction-associated fatty liver disease and gut dysbiosis: Pathophysiology, clinical implications, and emerging therapies. | Al-Busafi SA et al. | — | 2025 | → |
| Fatty Acids as Nutritional Therapy for NAFLD: A Bibliometric Analysis of Research Trends and Future Directions. | Huang Z et al. | — | 2025 | → |
| Flame retardant tricresyl phosphate gestational exposure induced endocrine and metabolic disruptions in rat. | Valentino SA et al. | — | 2025 | → |
| Fructose and follistatin potentiate acute MASLD during complete hepatic insulin resistance. | Tao R et al. | — | 2025 | → |
| Fructose-containing sugars and metabolic risk: a systematic review and meta-analysis. | Guntari P et al. | — | 2025 | → |
| Function of PNPLA3 I148M-Lessons From In Vivo Studies in Humans. | Yki-Järvinen H et al. | — | 2025 | → |
| Hemostatic alterations in metabolic dysfunction-associated steatotic liver disease (MASLD) and their link to venous thromboembolism (VTE). | González-Mendoza DE et al. | — | 2025 | → |
| Hepatic and Pancreatic Cellular Response to Early Life Nutritional Mismatch. | Ghosh S et al. | — | 2025 | → |
| Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications. | Truong XT et al. | — | 2025 | → |
| Hepatic Ketogenesis Regulates Lipid Homeostasis via ACSL1-mediated Fatty Acid Partitioning. | Mooli RGR et al. | — | 2025 | → |
| Hepatic sphingomyelin phosphodiesterase 3 promotes steatohepatitis by disrupting membrane sphingolipid metabolism. | Jiang J et al. | — | 2025 | → |
| Hepatic steatosis is associated with impaired hepatic glucose uptake under hyperglycemic conditions, a dynamic whole-body <sup>18</sup>F-FDG PET approach. | Basset-Sagarminaga J et al. | — | 2025 | → |
| Hepatocyte nuclear factors dynamically regulate triglyceride metabolic reprogramming in metabolic dysfunction-associated steatotic liver disease: Mechanisms and implications. | Li SQ et al. | — | 2025 | → |
| HFD Exacerbates Hepatic Lipid Metabolism Disorders After Cholecystectomy by Regulating the Bile Acid and Neutrophil Recruitment. | Xu Y et al. | — | 2025 | → |
| HIIT versus MICT in MASLD: mechanisms mediated by gut-liver axis crosstalk, mitochondrial dynamics remodeling, and adipokine signaling attenuation. | Deng D et al. | — | 2025 | → |
| Induction of Fructose Mediated De Novo Lipogenesis Coexists with the Upregulation of Mitochondrial Oxidative Function in Mice Livers. | Bhattacharjee P et al. | — | 2025 | → |
| Influence of triglycerides on the link between gamma-glutamyl transferase to high-density lipoprotein cholesterol ratio and nonalcoholic fatty liver disease in nonobese Chinese adults: A secondary cohort study. | Chen A et al. | — | 2025 | → |
| Intestinal Microbiota Modulation by Fecal Microbiota Transplantation in Nonalcoholic Fatty Liver Disease. | Hauser G et al. | — | 2025 | → |
| Investigating the Material Basis and Mechanisms of Toxicity Reduction in Processing and Compatibility of Euodiae Fructus Based on UPLC-MS/MS Quantitative Analysis and UHPLC-Q-TOF-MS Metabolomics. | Wang K et al. | — | 2025 | → |
| Involvement of Activin E depletion in metabolic dysfunction-associated steatohepatitis. | Sakaki M et al. | — | 2025 | → |
| Ketogenesis mitigates metabolic dysfunction-associated steatotic liver disease through mechanisms that extend beyond fat oxidation. | Queathem ED et al. | — | 2025 | → |
| Ketogenesis supports hepatic polyunsaturated fatty acid homeostasis via fatty acid elongation. | Queathem ED et al. | — | 2025 | → |
| KRT23 as a Potential Target for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): Evidence From Bioinformatics Analysis, Human Gene Polymorphism and Animal Experiments. | Hao Y et al. | — | 2025 | → |
| Linking Cardiovascular Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): The Role of Cardiometabolic Drugs in MASLD Treatment. | Zisis M et al. | — | 2025 | → |
| Lipid Accumulation and Insulin Resistance: Bridging Metabolic Dysfunction-Associated Fatty Liver Disease and Chronic Kidney Disease. | Cao X et al. | — | 2025 | → |
| Lipid-Lowering Potential of Almond Hulls (Quercetin, Baicalein, and Kaempferol): Insights from Network Pharmacology and Molecular Dynamics. | Miao Q et al. | — | 2025 | → |
| Lipid metabolism in cancer cells: Its role in hepatocellular carcinoma progression and therapeutic resistance. | Wong TL et al. | — | 2025 | → |
| Lipid profile and non-alcoholic fatty liver disease detected by ultrasonography: is systemic inflammation a necessary mediator? | Li W et al. | — | 2025 | → |
| Lipogenesis and MASLD: re-thinking the role of SREBPs. | Nakagawa H | — | 2025 | → |
| Lipotoxicity-driven metabolic dysfunction-associated steatotic liver disease (MASLD). | Iturbe-Rey S et al. | — | 2025 | → |
| Liver gene expression and its rewiring in hepatic steatosis are controlled by PI3Kα-dependent hepatocyte signaling. | Régnier M et al. | — | 2025 | → |
| Loss of endothelial ZEB2 in mice attenuates steatosis early during metabolic dysfunction-associated steatotic liver disease. | Dheedene W et al. | — | 2025 | → |
| Loss of Urat1 exacerbates APAP-induced liver injury in mice. | Zhao K et al. | — | 2025 | → |
| <i>Ppp1r3b</i> is a metabolic switch that shifts hepatic energy storage from lipid to glycogen. | Creasy KT et al. | — | 2025 | → |
| Luteolin Relieves Metabolic Dysfunction-Associated Fatty Liver Disease Caused by a High-Fat Diet in Rats Through Modulating the AdipoR1/AMPK/PPARγ Signaling Pathway. | Taweesap P et al. | — | 2025 | → |
| MASH as an emerging cause of hepatocellular carcinoma: current knowledge and future perspectives. | Karin M et al. | — | 2025 | → |
| Maternal metabolic dysfunction-associated steatotic liver disease during pregnancy and its impact on offspring steatosis. | Klepper CM et al. | — | 2025 | → |
| Mechanism of Semaglutide in MASLD Treatment: Where Is the Master Key? | Ezhilarasan D | — | 2025 | → |
| Metabolic-Associated Steatotic Liver Disease: From Molecular Mechanisms to Novel Therapies. | Cooper J et al. | — | 2025 | → |
| Metabolic Dysfunction-associated Steatotic Liver Disease Alters Fatty Acid Profiles in the Liver and Adipose Tissue. | Palomurto S et al. | — | 2025 | → |
| Metabolic dysfunction-associated steatotic liver disease: A pathophysiology and clinical framework to face the present and the future. | Corrao S et al. | — | 2025 | → |
| Metabolic Dysfunction-Associated Steatotic Liver Disease Complicated by Diabetes: Pathophysiology and Emerging Therapies. | Goto H et al. | — | 2025 | → |
| Metabolic Dysfunction-Associated Steatotic Liver Disease: From a Very Low-Density Lipoprotein Perspective. | Chen Y et al. | — | 2025 | → |
| Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment. | Stefan N et al. | — | 2025 | → |
| Metabolic dysfunction-associated steatotic liver disease in adults. | Huang DQ et al. | — | 2025 | → |
| Metabolic dysfunction-associated steatotic liver disease (MASLD) in children with obesity: An Obesity Medicine Association (OMA) and expert joint perspective 2025. | Panganiban J et al. | — | 2025 | → |
| Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Mechanisms, Clinical Implications and Therapeutic Advances. | Miller DM et al. | — | 2025 | → |
| Mitochondrial alterations and signatures in hepatocellular carcinoma. | Chen TH et al. | — | 2025 | → |
| Molecular Landscape and Diagnostic Model of MASH: Transcriptomic, Proteomic, Metabolomic, and Lipidomic Perspectives. | Chen Y et al. | — | 2025 | → |
| Molecular mechanisms in MASLD/MASH-related HCC. | Wang X et al. | — | 2025 | → |
| Molecular mechanisms of metabolic dysfunction-associated steatotic liver disease (MASLD): functional analysis of glucose and fructose metabolism pathways. | Rabbani N et al. | — | 2025 | → |
| Multifaceted Human Antigen R (HuR): A Key Player in Liver Metabolism and MASLD. | Eppler N et al. | — | 2025 | → |
| Multiple Roles of Palmitic Acid in Cardiovascular Diseases. | Jiang H et al. | — | 2025 | → |
| NAFLD vs MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)-Why the Need for a Change of Nomenclature? | Gastaldelli A et al. | — | 2025 | → |
| Naringenin Decreases Retroperitoneal Adiposity and Improves Metabolic Parameters in a Rat Model of Western Diet-Induced Obesity. | López-Almada G et al. | — | 2025 | → |
| Natural History of Metabolic Dysfunction-Associated Steatotic Liver Disease: From Metabolic Syndrome to Hepatocellular Carcinoma. | Alpízar Salazar M et al. | — | 2025 | → |
| Neurotensin promotes hepatic steatosis by regulating lipid uptake and mitochondrial adaptation in hepatocytes. | Banerjee M et al. | — | 2025 | → |
| Nicotinamide Adenine Dinucleotide Phosphate Oxidases and Metabolic Dysfunction-Associated Steatotic Liver Disease. | Cammisotto V et al. | — | 2025 | → |
| Nicotinic acid increases adipose tissue dietary fatty acid trapping and reduces postprandial hepatic and cardiac fatty acid uptake in prediabetes. | Montastier É et al. | — | 2025 | → |
| Nutrient-Induced Changes of Liver Fat Content in Humans. | Kovář J et al. | — | 2025 | → |
| Paraoxonase-like APMAP maintains endoplasmic-reticulum-associated lipid and lipoprotein homeostasis. | Paul B et al. | — | 2025 | → |
| Pathophysiological underpinnings of metabolic dysfunction-associated steatotic liver disease. | Kuchay MS et al. | — | 2025 | → |
| Pharmacological treatment options for metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus: A systematic review. | Konings LAM et al. | — | 2025 | → |
| Practical Approaches to Managing Dyslipidemia in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease. | Bril F et al. | — | 2025 | → |
| Predictive Value of the Triglyceride-Glucose Index for Metabolic-Associated Fatty Liver Disease in Individuals with Different Metabolic Obese Phenotypes. | Lv D et al. | — | 2025 | → |
| Prevalence of Nonalcoholic Fatty Liver Disease in Obese Patients and its Association with Insulin Resistance Markers. | Nayak J et al. | — | 2025 | → |
| Probiotic Supplementation Alleviates Corticosterone-Induced Fatty Liver Disease by Regulating Hepatic Lipogenesis and Increasing Gut Microbiota Diversity in Broilers. | Feng Y et al. | — | 2025 | → |
| Proline enhances the hepatic induction of lipogenic gene expression in male hepatic fasn reporter mice. | Taniguchi A et al. | — | 2025 | → |
| Quercetin and <i>Camellia sinensis</i> leaf extract ameliorates liver steatosis in high-fat diet fed mice via suppression of oxidative stress and inflammation. | Badiee MS et al. | — | 2025 | → |
| Quick glance at 'metabolic dysfunction associated steatotic liver disease' therapeutics: Targets, trials, and trends. | Zacharia GS et al. | — | 2025 | → |
| RAP1A suppresses hepatic steatosis by regulating amino acid-mediated mTORC1 activation. | Agarwal H et al. | — | 2025 | → |
| Reactive Oxygen Species as Key Molecules in the Pathogenesis of Alcoholic Fatty Liver Disease and Nonalcoholic Fatty Liver Disease: Future Perspectives. | Zhang Z et al. | — | 2025 | → |
| Reconciling the apparently contrasting observational and genetic evidence on the association between MASLD and cardiovascular disease. | Brouwers MCGJ | — | 2025 | → |
| Relationship between MASLD and women's health: A review. | Jancova P et al. | — | 2025 | → |
| Replacing dietary carbohydrate with protein and fat improves lipoprotein subclass profile and liver fat in type 2 diabetes independent of body weight: evidence from 2 randomized controlled trials. | Thomsen MN et al. | — | 2025 | → |
| Reply to: "Plasma metabolomics promises to facilitate precise prevention of MASH and mortality from liver disease". | Huang Q et al. | — | 2025 | → |
| Resveratrol protection against cardiac remodeling and ischemia-reperfusion injury associated with hepatic lipid metabolism ameliorations and adipose tissue autotaxin pathway inhibition in a diet induced prediabetic female rat model. | Jouenne A et al. | — | 2025 | → |
| Review of roles of RNA-binding proteins on NAFLD and the related pharmaceutical measures. | Li C et al. | — | 2025 | → |
| Role of genetic variants and DNA methylation of lipid metabolism-related genes in metabolic dysfunction-associated steatotic liver disease. | Wang JJ et al. | — | 2025 | → |
| Selenium-enriched Lactiplantibacillus plantarum alleviates alkalinity stress-induced selective hepatic insulin resistance in common carp. | Che X et al. | — | 2025 | → |
| Serum polychlorinated biphenyls as a risk factor for MASLD: Exploring the association and underlying mechanisms. | Yang R et al. | — | 2025 | → |
| Skeletal Muscle and Cardiovascular Health. | Ruiz-Ramie J et al. | — | 2025 | → |
| Skeletal muscle and MASLD: Mechanistic and clinical insights. | Marjot T et al. | — | 2025 | → |
| Spatial regulation of glucose and lipid metabolism by hepatic insulin signaling. | He B et al. | — | 2025 | → |
| SR-A3 suppresses AKT activation to protect against MAFLD by inhibiting XIAP-mediated PTEN degradation. | Lai P et al. | — | 2025 | → |
| Stabilizing hepatic fatty acid oxidation: Editorial on "USP29 alleviates the progression of MASLD by stabilizing ACSL5 through K48 deubiquitination". | Choi MG et al. | — | 2025 | → |
| Statin-associated regulation of hepatic PNPLA3 in patients without known liver disease. | Ahmed O et al. | — | 2025 | → |
| Submicron Dispersions of Phytosterols Reverse Liver Steatosis with Higher Efficacy than Phytosterol Esters in a Diet Induced-Fatty Liver Murine Model. | Gillet R et al. | — | 2025 | → |
| Sympathetic activation of adipose tissue lipolysis underlies overnutrition-induced metabolic dysfunction. | Luukkonen PK | — | 2025 | → |
| Systematic profiling reveals hepatic immune and metabolic dysregulation in DNASE1L3-deficient mice. | Lei L et al. | — | 2025 | → |
| Targeted Degradation Technologies Utilizing Autophagy. | Zhou Z et al. | — | 2025 | → |
| Targeted inhibition of hepatic de novo ceramide synthesis ameliorates MASH. | Yu X et al. | — | 2025 | → |
| Targeted metabolomics reveals bioactive inflammatory mediators from gut into blood circulation in children with NAFLD. | Luo M et al. | — | 2025 | → |
| Targeting regulation of lipid metabolism with polysaccharide of traditional Chinese medicine for the treatment of non-alcoholic fatty liver disease: A review. | Liu W et al. | — | 2025 | → |
| Targeting the AMP-activated protein kinase pathway: the active metabolites of botanical drugs represent potential strategies for treating metabolic-associated fatty liver disease. | Liang Q et al. | — | 2025 | → |
| Targeting the gut microbiota and lipid metabolism: potential mechanisms of natural products for the treatment of non-alcoholic fatty liver disease. | Zhang Y et al. | — | 2025 | → |
| Targeting the PI3K/AKT signaling pathway: an important molecular mechanism of herbal medicine in the treatment of MASLD/MASH. | Jiang S et al. | — | 2025 | → |
| The application of procyanidins in diabetes and its complications: a review of preclinical studies. | Zhang Y et al. | — | 2025 | → |
| The clinical value of serum sirtuin-1 concentration in the diagnosis of metabolic dysfunction-associated steatotic liver disease. | Amirkhizi F et al. | — | 2025 | → |
| The enedioic acid analog 326E alleviates metabolic dysfunction-associated steatohepatitis via dual targeting at ACLY and PPARα. | Xie Z et al. | — | 2025 | → |
| The hepatic expression status of hepatocyte nuclear factor 4α in subclinical and clinical ketotic dairy cows and its impact on lipid metabolism in hepatocytes. | Chen M et al. | — | 2025 | → |
| The ins and outs of liver fat metabolism: The effect of phenotype and diet on risk of intrahepatic triglyceride accumulation. | Smith K et al. | — | 2025 | → |
| The Management of Cardiometabolic Risk in MAFLD: Therapeutic Strategies to Modulate Deranged Metabolism and Cholesterol Levels. | Pezzoli A et al. | — | 2025 | → |
| The Onset of Steatosis Occurs as Early as Seven Days and Progresses to Nonalcoholic Steatohepatitis in a Pediatric Pig Model of Nonalcoholic Fatty Liver Disease. | Yadav R et al. | — | 2025 | → |
| The physiology of MASLD: molecular pathways between liver and adipose tissues. | Lee WH et al. | — | 2025 | → |
| The predictive value of triglyceride-glucose-high density lipoprotein-body mass index (TGH-BMI) for different degrees of hepatic steatosis and liver fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD). | Li Y et al. | — | 2025 | → |
| Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH). | Do A et al. | — | 2025 | → |
| Thermoneutral housing worsens MASLD and reveals defective brown adipose tissue response to β3-adrenergic stimulation. | Martin CMP et al. | — | 2025 | → |
| The role of hypothalamus in the pathophysiological process of MASLD and advances in drug discovery. | Wei S et al. | — | 2025 | → |
| Three-Dimensional Dynamic Cell Models for Metabolic Dysfunction-Associated Steatotic Liver Disease Progression. | Huang Z et al. | — | 2025 | → |
| Thyroid hormone action and liver disease, a complex interplay. | Marino L et al. | — | 2025 | → |
| Totum-448 Improves MASLD and Modulates Microbiota in Hamsters: Dose-Response Study and Effects of Supplementation Cessation. | Chavanelle V et al. | — | 2025 | → |
| Transcriptomic Profiling of mRNAs, circRNAs, and lncRNAs in Mouse Liver at the Early Stage of Echinococcus multilocularis Infection. | Li XR et al. | — | 2025 | → |
| Treating metabolic dysfunction-associated steatohepatitis: The fat-trimming FGF21 approach. | Li X et al. | — | 2025 | → |
| TREM2 in MASH: integrating lipid metabolism and immune response. | Shi S et al. | — | 2025 | → |
| Tspo Depletion Exacerbates Steatosis Through Fatty Acid Uptake. | Li Y et al. | — | 2025 | → |
| Unraveling the Gut-Liver-Brain Axis: Microbiome, Inflammation, and Emerging Therapeutic Approaches. | Aghara H et al. | — | 2025 | → |
| VLDL lipidomics reveals hepatocellular lipidome changes in metabolic dysfunction-associated steatotic liver disease. | Guardamino Ojeda D et al. | — | 2025 | → |
| Weight loss in MASLD restores the balance of liver fatty acid sources. | Lambert JE et al. | — | 2025 | → |
| YBX1/CD36 positive feedback loop-mediated lipid accumulation drives metabolic dysfunction-associated steatotic liver disease. | Zhang Q et al. | — | 2025 | → |
| Zebrafish model of palmitic acid induced MAFLD recapitulates pathways conserved in mice and humans. | Bhattacharya D et al. | — | 2025 | → |
| 6-Gingerol Inhibits De Novo Lipogenesis by Targeting Stearoyl-CoA Desaturase to Alleviate Fructose-Induced Hepatic Steatosis. | Li P et al. | — | 2024 | → |
| 6-Gingerol regulates triglyceride and cholesterol biosynthesis to improve hepatic steatosis in MAFLD by activating the AMPK-SREBPs signaling pathway. | Xia Q et al. | — | 2024 | → |
| A combined extract containing <i>Schisandra chinensis</i> (SCE) reduced hepatic triglyceride accumulation in rats fed a high-sucrose diet. | Lee H et al. | — | 2024 | → |
| A Comprehensive Analysis of Liver Lipidomics Signature in Adults with Metabolic Dysfunction-Associated Steatohepatitis-A Pilot Study. | Mouskeftara T et al. | — | 2024 | → |
| A comprehensive approach to lifestyle intervention based on a calorie-restricted diet ameliorates liver fat in overweight/obese patients with NAFLD: a multicenter randomized controlled trial in China. | Liu Z et al. | — | 2024 | → |
| Adipose tissue in cortisol excess: What Cushing's syndrome can teach us? | Bavaresco A et al. | — | 2024 | → |
| Adipose Tissue Insulin Resistance Correlates with Disease Severity in Pediatric Metabolic Dysfunction-Associated Steatotic Liver Disease: A Prospective Cohort Study. | Heldens A et al. | — | 2024 | → |
| Adipose tissue insulin resistance in children and adolescents: linking glucose and free fatty acid metabolism to hepatic injury markers. | Bonet J et al. | — | 2024 | → |
| Adiposity, type 2 diabetes and atherosclerotic cardiovascular disease risk: Use and abuse of the body mass index. | Arsenault BJ et al. | — | 2024 | → |
| Advances and challenges in measuring hepatic glucose uptake with FDG PET: implications for diabetes research. | Basset-Sagarminaga J et al. | — | 2024 | → |
| Age at menopause and risk of metabolic dysfunction-associated fatty liver disease: A 14-year cohort study. | Kim EY et al. | — | 2024 | → |
| A genetic mouse model of lean-NAFLD unveils sexual dimorphism in the liver-heart axis. | Burelle C et al. | — | 2024 | → |
| Altered Metabolites in Hepatocellular Carcinoma (HCC) Paving the Road for Metabolomics Signature and Biomarkers for Early Diagnosis of HCC. | Al-Amodi HS et al. | — | 2024 | → |
| An ER-targeted, Viscosity-sensitive Hemicyanine Dye for the Diagnosis of Nonalcoholic Fatty Liver and Photodynamic Cancer Therapy by Activating Pyroptosis Pathway. | Zeng S et al. | — | 2024 | → |
| A New Non-Obese Steatohepatitis Mouse Model with Cardiac Dysfunction Induced by Addition of Ethanol to a High-Fat/High-Cholesterol Diet. | Shiraishi S et al. | — | 2024 | → |
| A novel Alisma orientale extract alleviates non-alcoholic steatohepatitis in mice via modulation of PPARα signaling pathway. | Xie Y et al. | — | 2024 | → |
| ApoL6 associates with lipid droplets and disrupts Perilipin1-HSL interaction to inhibit lipolysis. | Wang Y et al. | — | 2024 | → |
| Application and mechanism of Chinese herb medicine in the treatment of non-alcoholic fatty liver disease. | Liu Y et al. | — | 2024 | → |
| Association between triglyceride glucose-body mass index and the staging of non-alcoholic steatohepatitis and fibrosis in patients with non-alcoholic fatty liver disease. | Zhang F et al. | — | 2024 | → |
| Associations of ALT/AST, a marker of hepatosteatosis, with pulse rate in young women and with blood pressure in middle-aged women independently of abdominal fat accumulation and insulin resistance. | Minato-Inokawa S et al. | — | 2024 | → |
| Association with the plasma atherogenic index with hepatic steatosis and fibrosis in the US population. | Li Y et al. | — | 2024 | → |
| A unified framework for prediction of liver steatosis dynamics in response to different diet and drug interventions. | Simonsson C et al. | — | 2024 | → |
| Beneficial Effects of Capybara Oil Supplementation on Steatosis and Liver Apoptosis in Obese Mice. | Lontro Alves L et al. | — | 2024 | → |
| Berberine ameliorates glucocorticoid-induced hyperglycemia: an in vitro and in vivo study. | Gupta M et al. | — | 2024 | → |
| Body Fat Depletion: the Yin Paradigm for Treating Type 2 Diabetes. | Zhu J et al. | — | 2024 | → |
| Cellular Senescence and Extracellular Vesicles in the Pathogenesis and Treatment of Obesity-A Narrative Review. | Liang Y et al. | — | 2024 | → |
| CETP-derived Peptide Seq-1, the Key Component of HB-ATV-8 Vaccine Prevents Stress Responses, and Promotes Downregulation of Pro-Fibrotic Genes in Hepatocytes and Stellate Cells. | Calixto-Tlacomulco S et al. | — | 2024 | → |
| Coagulation Factor VII Fine-tunes Hepatic Steatosis by Blocking AKT-CD36-Mediated Fatty Acid Uptake. | Zhang Y et al. | — | 2024 | → |
| Common Denominator of MASLD and Some Non-Communicable Diseases. | Ferenc K et al. | — | 2024 | → |
| Comparison of HepaRG and HepG2 cell lines to model mitochondrial respiratory adaptations in non‑alcoholic fatty liver disease. | Maseko TE et al. | — | 2024 | → |
| Complete inhibition of liver acetyl-CoA carboxylase activity is required to exacerbate liver tumorigenesis in mice treated with diethylnitrosamine. | Shrestha R et al. | — | 2024 | → |
| Crosstalk in extrahepatic and hepatic system in NAFLD/NASH. | Duan Y et al. | — | 2024 | → |
| Deciphering the molecular pathways of saroglitazar: A dual PPAR α/γ agonist for managing metabolic NAFLD. | Ezhilarasan D | — | 2024 | → |
| Diabetes mellitus-Progress and opportunities in the evolving epidemic. | Abel ED et al. | — | 2024 | → |
| [Diagnosis and evaluation of metabolic dysfunction associated steatotic liver disease (MASLD)]. | Canivet CM et al. | — | 2024 | → |
| Dietary acid load and cirrhosis-related mortality: a prospective cohort study. | Pashayee-Khamene F et al. | — | 2024 | → |
| Dietary Pattern's Role in Hepatic Epigenetic and Dietary Recommendations for the Prevention of NAFLD. | Martín Barraza JI et al. | — | 2024 | → |
| Disruption of Melatonin Signaling Leads to Lipids Accumulation in the Liver of Melatonin Proficient Mice. | Goyal V et al. | — | 2024 | → |
| Dissociation between liver fat content and fasting metabolic markers of selective hepatic insulin resistance in humans. | Westcott FA et al. | — | 2024 | → |
| Diverting hepatic lipid fluxes with lifestyles revision and pharmacological interventions as a strategy to tackle steatotic liver disease (SLD) and hepatocellular carcinoma (HCC). | Misceo D et al. | — | 2024 | → |
| Dual Role of Pregnane X Receptor in Nonalcoholic Fatty Liver Disease. | Xu Y et al. | — | 2024 | → |
| Dynamic changes in the mouse hepatic lipidome following warm ischemia reperfusion injury. | Liss KHH et al. | — | 2024 | → |
| Effects of a High Trans Fatty Acid Diet on Kidney-, Liver-, and Heart-Associated Diseases in a Rabbit Model. | Ismail H et al. | — | 2024 | → |
| Effects of NPY-2 Receptor Antagonists, Semaglutide, PYY<sub>3-36</sub>, and Empagliflozin on Early MASLD in Diet-Induced Obese Rats. | Kloock S et al. | — | 2024 | → |
| Effects of riboflavin deficiency and high dietary fat on hepatic lipid accumulation: a synergetic action in the development of non-alcoholic fatty liver disease. | Wang Y et al. | — | 2024 | → |
| Emerging role of lipophagy in liver disorders. | Nazeer B et al. | — | 2024 | → |
| Empagliflozin mitigates metabolic dysfunction-associated steatotic liver disease by reducing de novo lipogenesis in a mouse model of lipoatrophic diabetes. | Smati S et al. | — | 2024 | → |
| Erchen decoction alleviates the progression of NAFLD by inhibiting lipid accumulation and iron overload through Caveolin-1 signaling. | Deng G et al. | — | 2024 | → |
| Excessive free fatty acid sensing in pituitary lactotrophs elicits steatotic liver disease by decreasing prolactin levels. | Ji X et al. | — | 2024 | → |
| Exosome prospects in the diagnosis and treatment of non-alcoholic fatty liver disease. | Tamimi A et al. | — | 2024 | → |
| Exploration of the Key Genes Involved in Non-alcoholic Fatty Liver Disease and Possible MicroRNA Therapeutic Targets. | Mahmoudi A et al. | — | 2024 | → |
| Exploring the impact of lipid droplets on the evolution and progress of hepatocarcinoma. | Maurotti S et al. | — | 2024 | → |
| Fatty acid synthesis suppresses dietary polyunsaturated fatty acid use. | Worthmann A et al. | — | 2024 | → |
| FGF21-mediated autophagy: Remodeling the homeostasis in response to stress in liver diseases. | Shen W et al. | — | 2024 | → |
| Formononetin promotes fatty acid β-oxidation to treat non-alcoholic steatohepatitis through SIRT1/PGC-1α/PPARα pathway. | Liao J et al. | — | 2024 | → |
| From petals to healing: consolidated network pharmacology and molecular docking investigations of the mechanisms underpinning <i>Rhododendron arboreum</i> flower's anti-NAFLD effects. | Jangwan NS et al. | — | 2024 | → |
| Fruit and vegetable intake and the risk of non-alcoholic fatty liver disease: a meta-analysis of observational studies. | Wang R et al. | — | 2024 | → |
| Gegen Qinlian Decoction Modulates Atherosclerosis and Lipid Metabolism Through Cellular Interplay and Signaling Pathways. | Zhang Z et al. | — | 2024 | → |
| Gestational and Developmental Contributors of Pediatric MASLD. | Mouzaki M et al. | — | 2024 | → |
| Gestational diabetes mellitus and development of intergenerational non-alcoholic fatty liver disease (NAFLD) after delivery: a systematic review and meta-analysis. | Foo RX et al. | — | 2024 | → |
| GLP-1 Receptor Agonist Treatment Improves Fasting and Postprandial Lipidomic Profiles Independently of Diabetes and Weight Loss. | Della Pepa G et al. | — | 2024 | → |
| Glycerol Kinase Drives Hepatic de novo Lipogenesis and Triglyceride Synthesis in Nonalcoholic Fatty Liver by Activating SREBP-1c Transcription, Upregulating DGAT1/2 Expression, and Promoting Glycerol Metabolism. | Ouyang S et al. | — | 2024 | → |
| Greater oxidation of dietary linoleate compared to palmitate in humans following an acute high-carbohydrate diet. | Srnic N et al. | — | 2024 | → |
| Hepatic fatty acid and glucose handling in metabolic disease: Potential impact on cardiovascular disease risk. | Westcott F et al. | — | 2024 | → |
| Hepatic glucokinase regulatory protein and carbohydrate response element binding protein attenuation reduce de novo lipogenesis but do not mitigate intrahepatic triglyceride accumulation in Aldob deficiency. | Buziau AM et al. | — | 2024 | → |
| Hepatic glucose metabolism in the steatotic liver. | Scoditti E et al. | — | 2024 | → |
| Hepatic glucose production rises with the histological severity of metabolic dysfunction-associated steatohepatitis. | Sabatini S et al. | — | 2024 | → |
| Hepatic mitochondrial reductive stress in the pathogenesis and treatment of steatotic liver disease. | Jokinen MJ et al. | — | 2024 | → |
| Hepatic selective insulin resistance at the intersection of insulin signaling and metabolic dysfunction-associated steatotic liver disease. | Bo T et al. | — | 2024 | → |
| Hepatocyte-specific loss of melanocortin 1 receptor disturbs fatty acid metabolism and promotes adipocyte hypertrophy. | Thapa K et al. | — | 2024 | → |
| Hexane insoluble fraction from purple rice extract improves steatohepatitis and fibrosis <i>via</i> inhibition of NF-κB and JNK signaling. | Naiki-Ito A et al. | — | 2024 | → |
| High-fat-diet-induced hepatic insulin resistance <i>per se</i> attenuates murine <i>de novo</i> lipogenesis. | Goedeke L et al. | — | 2024 | → |
| High sucrose intake exacerbates airway inflammation through pathogenic Th2 and Th17 response in ovalbumin (OVA)-induced acute allergic asthma in C57BL/6 mice. | Kim HJ et al. | — | 2024 | → |
| Histological improvements following energy restriction and exercise: The role of insulin resistance in resolution of MASH. | Mucinski JM et al. | — | 2024 | → |
| Hugan Qingzhi tablets attenuates endoplasmic reticulum stress in nonalcoholic fatty liver disease rats by regulating PERK and ATF6 pathways. | Yang M et al. | — | 2024 | → |
| (<i>E</i>)-5-hydroxy-7-methoxy-3-(2-hydroxybenzyl)-4-chromanone, a Major Homoisoflavonoid, Attenuates Free Fatty Acid-Induced Hepatic Steatosis by Activating AMPK and PPARα Pathways in HepG2 Cells. | Park JE et al. | — | 2024 | → |
| IGFBP2 functions as an endogenous protector against hepatic steatosis via suppression of the EGFR-STAT3 pathway. | Zhai T et al. | — | 2024 | → |
| Implications of Protein and Sarcopenia in the Prognosis, Treatment, and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). | Singh A et al. | — | 2024 | → |
| Influence of Lipid Class Used for Omega-3 Fatty Acid Supplementation on Liver Fat Accumulation in MASLD. | Sabinari I et al. | — | 2024 | → |
| Insulin resistance and Metabolic dysfunction-associated steatotic liver disease (MASLD): Pathways of action of hypoglycemic agents. | Maldonado-Rojas ADC et al. | — | 2024 | → |
| Insulin Resistance, Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Clinical and Experimental Perspective. | Jung I et al. | — | 2024 | → |
| Integration of network pharmacology, lipidomics, and transcriptomics analysis to reveal the mechanisms underlying the amelioration of AKT-induced nonalcoholic fatty liver disease by total flavonoids in vine tea. | Du S et al. | — | 2024 | → |
| Interaction between fatty acid oxidation and ethanol metabolism in liver. | Lu Y et al. | — | 2024 | → |
| Interventions Targeting Insulin Resistance in Patients with Type 1 Diabetes: A Narrative Review. | Herascu A et al. | — | 2024 | → |
| Lactate transporter MCT1 in hepatic stellate cells promotes fibrotic collagen expression in nonalcoholic steatohepatitis. | Min K et al. | — | 2024 | → |
| Lipid-associated macrophages between aggravation and alleviation of metabolic diseases. | Xu R et al. | — | 2024 | → |
| Lipid metabolism indicators provide tools for the diagnosis of non-alcoholic fatty liver disease: results of a nationwide survey. | Wang Y et al. | — | 2024 | → |
| Lipid metabolism in MASLD and MASH: From mechanism to the clinic. | Carli F et al. | — | 2024 | → |
| Lipid metabolism in the immune niche of tumor-prone liver microenvironment. | Chen J et al. | — | 2024 | → |
| Lipoprotein Lipidomics as a Frontier in Non-Alcoholic Fatty Liver Disease Biomarker Discovery. | Herrera-Marcos LV et al. | — | 2024 | → |
| Liver proteomics identifies a disconnect between proteins associated with de novo lipogenesis and triglyceride storage. | Small L et al. | — | 2024 | → |
| Long Noncoding RNAs in Diet-Induced Metabolic Diseases. | Brandt A et al. | — | 2024 | → |
| Low phosphorus increases hepatic lipid deposition, oxidative stress and inflammatory response via Acetyl-CoA carboxylase-dependent manner in zebrafish liver cells. | Lin J et al. | — | 2024 | → |
| Mechanisms coupling lipid droplets to MASLD pathophysiology. | Reid MV et al. | — | 2024 | → |
| Mediterranean diet for the management of metabolic dysfunction-associated steatotic liver disease in non-Mediterranean, Western countries: What's known and what's needed? | Sualeheen A et al. | — | 2024 | → |
| Medium chain triglycerides alleviate non-alcoholic fatty liver disease through bile acid-mediated FXR signaling pathway: A comparative study with common vegetable edible oils. | Yue H et al. | — | 2024 | → |
| Melatonin restores hepatic lipid metabolic homeostasis disrupted by blue light at night in high-fat diet-fed mice. | Guan Q et al. | — | 2024 | → |
| Metabolic Dysfunction-Associated Steatohepatitis and Progression to Hepatocellular Carcinoma: A Literature Review. | Ghazanfar H et al. | — | 2024 | → |
| Metabolic Dysfunction-Associated Steatotic Liver Disease: From Pathogenesis to Current Therapeutic Options. | Portincasa P et al. | — | 2024 | → |
| Metabolic Signatures of Blood Pressure and Risk of Cardiovascular Diseases. | Manou M et al. | — | 2024 | → |
| Metabolic Syndrome and Biotherapeutic Activity of Dairy (Cow and Buffalo) Milk Proteins and Peptides: Fast Food-Induced Obesity Perspective-A Narrative Review. | Abdisa KB et al. | — | 2024 | → |
| Metabolomics at the cutting edge of risk prediction of MASLD. | Tan EY et al. | — | 2024 | → |
| Mitochondria-targeted hydrogen sulfide donor reduces fatty liver and obesity in mice fed a high fat diet by inhibiting de novo lipogenesis and inflammation via mTOR/SREBP-1 and NF-κB signaling pathways. | Stachowicz A et al. | — | 2024 | → |
| Modelling and assessment of glucose-lactate kinetics in youth with overweight, obesity and metabolic dysfunction-associated steatotic liver disease: A pilot study. | Bonet J et al. | — | 2024 | → |
| Molecular Insights into the Inhibition of Lipid Accumulation in Hepatocytes by Unique Extracts of Ashwagandha. | Li D et al. | — | 2024 | → |
| Mulberry and <i>Hippophae</i>-based solid beverage attenuate hyperlipidemia and hepatic steatosis via adipose tissue-liver axis. | Zhu AQ et al. | — | 2024 | → |
| Myosteatosis: Diagnosis, pathophysiology and consequences in metabolic dysfunction-associated steatotic liver disease. | Henin G et al. | — | 2024 | → |
| Narrative Review of Immunomodulatory and Anti-inflammatory Effects of Sodium-Glucose Cotransporter 2 Inhibitors: Unveiling Novel Therapeutic Frontiers. | Lee SA et al. | — | 2024 | → |
| Natural history and progression of metabolic dysfunction-associated steatotic liver disease. | Hagström H et al. | — | 2024 | → |
| Navigating nonalcoholic fatty liver disease (NAFLD): Exploring the roles of estrogens, pharmacological and medical interventions, and life style. | Zuo Q et al. | — | 2024 | → |
| New advances in drug development for metabolic dysfunction-associated diseases and alcohol-associated liver disease. | Zhang J et al. | — | 2024 | → |
| New approaches to the treatment of metabolic dysfunction-associated steatotic liver with natural products. | Yadav P et al. | — | 2024 | → |
| Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Causation or Association. | Bali AD et al. | — | 2024 | → |
| Nonalcoholic Fatty Liver Disease and Staging of Hepatic Fibrosis. | Engin A | — | 2024 | → |
| Non-Alcoholic Fatty Liver Disease Induced by Feeding Medium-Chain Fatty Acids Upregulates Cholesterol and Lipid Homeostatic Genes in Skeletal Muscle of Neonatal Pigs. | Gerrard SD et al. | — | 2024 | → |
| Non-alcoholic fatty liver disease in patients with morbid obesity: the gut microbiota axis as a potential pathophysiology mechanism. | Cornejo-Pareja I et al. | — | 2024 | → |
| Non-Invasive Serum Markers of Non-Alcoholic Fatty Liver Disease Fibrosis: Potential Tools for Detecting Patients with Cardiovascular Disease. | Chen LZ et al. | — | 2024 | → |
| Non-Pharmacological Approach to Diet and Exercise in Metabolic-Associated Fatty Liver Disease: Bridging the Gap between Research and Clinical Practice. | Ali H et al. | — | 2024 | → |
| Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? | Huttasch M et al. | — | 2024 | → |
| Oligonucleotide therapies for nonalcoholic steatohepatitis. | Li S et al. | — | 2024 | → |
| Pharmacologic inhibition of lipogenesis for the treatment of NAFLD. | Esler WP et al. | — | 2024 | → |
| Phenotypic and metabolomic characteristics of mouse models of metabolic associated steatohepatitis. | Yang CR et al. | — | 2024 | → |
| PNPLA3 is a triglyceride lipase that mobilizes polyunsaturated fatty acids to facilitate hepatic secretion of large-sized very low-density lipoprotein. | Johnson SM et al. | — | 2024 | → |
| Polyoxometalates Ameliorate Metabolic Dysfunction-Associated Steatotic Liver Disease by Activating the AMPK Signaling Pathway. | Wang D et al. | — | 2024 | → |
| Predictive value of the triglyceride-glucose index for metabolic-associated fatty liver disease in individuals with different metabolic obese phenotypes | Lv D et al. | — | 2024 | — |
| Prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) in a middle-aged population with overweight and normal liver enzymes, and diagnostic accuracy of noninvasive proxies. | van Son KC et al. | — | 2024 | → |
| Preventing High Fat Diet-Induced Obesity and Related Hepatic Steatosis by Chlorin e6-Mediated Photodynamic Therapy. | Gurung P et al. | — | 2024 | → |
| Prevotella and succinate treatments altered gut microbiota, increased laying performance, and suppressed hepatic lipid accumulation in laying hens. | Liu M et al. | — | 2024 | → |
| Proanthocyanidins-Based Synbiotics as a Novel Strategy for Nonalcoholic Fatty Liver Disease (NAFLD) Risk Reduction. | Thilakarathna WPDW et al. | — | 2024 | → |
| Protein kinase D2 modulates hepatic insulin sensitivity in male mice. | Rada P et al. | — | 2024 | → |
| Regulation of hepatic lipogenesis by asymmetric arginine methylation. | Han HS et al. | — | 2024 | → |
| Role of Insulin Resistance in the Development of Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: From Bench to Patient Care. | Nogueira JP et al. | — | 2024 | → |
| Role of Neutrophils in the Development of Steatotic Liver Disease. | Choi YJ et al. | — | 2024 | → |
| Role of plasma metabolome in mediating the effect of plasma lipidome on NAFLD: a Mendelian randomization study. | Zheng Z et al. | — | 2024 | → |
| Semaglutide Treatment Effects on Liver Fat Content in Obese Subjects with Metabolic-Associated Steatotic Liver Disease (MASLD). | Dusilová T et al. | — | 2024 | → |
| Serum isthmin-1 is a potential biomarker for metabolic dysfunction associated fatty liver disease in patients with metabolic syndrome and type 2 diabetes mellitus. | Lei X et al. | — | 2024 | → |
| Sex Differences in the Association Between AST/ALT and Incidence of Type 2 Diabetes in Japanese Patients with Nonalcoholic Fatty Liver Disease: A Retrospective Cohort Study. | Zhang C et al. | — | 2024 | → |
| Some paradoxes and unresolved aspects of hepatic de novo lipogenesis. | Jones JG | — | 2024 | → |
| Spatial lipidomics reveals zone-specific hepatic lipid alteration and remodeling in metabolic dysfunction-associated steatohepatitis. | Seubnooch P et al. | — | 2024 | → |
| Spatial single-cell isotope tracing reveals heterogeneity of de novo fatty acid synthesis in cancer. | Buglakova E et al. | — | 2024 | → |
| Spatial Transcriptomic Study Reveals Heterogeneous Metabolic Adaptation and a Role of Pericentral PPARα/CAR/Ces2a Axis During Fasting in Mouse Liver. | Wang S et al. | — | 2024 | → |
| Strategy for treating MAFLD: Electroacupuncture alleviates hepatic steatosis and fibrosis by enhancing AMPK mediated glycolipid metabolism and autophagy in T2DM rats. | Duan H et al. | — | 2024 | → |
| Supplementation of Micro- and Macronutrients-A Role of Nutritional Status in Non-Alcoholic Fatty Liver Disease. | Tyczyńska M et al. | — | 2024 | → |
| Suppression of hepatic ChREBP⍺-CYP2C50 axis-driven fatty acid oxidation sensitizes mice to diet-induced MASLD/MASH. | Zhang D et al. | — | 2024 | → |
| Surveillance of the liver in type 2 diabetes: important but unfeasible? | Qadri S et al. | — | 2024 | → |
| Targeting acetyl-CoA carboxylases for the treatment of MASLD. | Mateo-Marín MA et al. | — | 2024 | → |
| The first MASH drug therapy on the horizon: Current perspectives of resmetirom. | Petta S et al. | — | 2024 | → |
| The Link Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Gastroesophageal Reflux Disease. | Dutta P et al. | — | 2024 | → |
| The mitochondrial TSPO ligand Atriol mitigates metabolic-associated steatohepatitis by downregulating CXCL1. | Li Y et al. | — | 2024 | → |
| The pathophysiology of MASLD: an immunometabolic perspective. | Schwärzler J et al. | — | 2024 | → |
| The plasma lipidome varies with the severity of metabolic dysfunction-associated steatotic liver disease. | Heymann CJF et al. | — | 2024 | → |
| Therapeutic perspectives on PDE4B inhibition in adipose tissue dysfunction and chronic liver injury. | Staller DW et al. | — | 2024 | → |
| Therapeutic potential of traditional Chinese medicine in the prevention and treatment of digestive inflammatory cancer transformation: Portulaca oleracea L. as a promising drug. | Shao G et al. | — | 2024 | → |
| The Relationship between Pathogenesis and Possible Treatments for the MASLD-Cirrhosis Spectrum. | Vidal-Cevallos P et al. | — | 2024 | → |
| The role of adipose tissue dysfunction in hepatic insulin resistance and T2D. | Sancar G et al. | — | 2024 | → |
| The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review. | Zachou M et al. | — | 2024 | → |
| The role of FGF21 in the interplay between obesity and non-alcoholic fatty liver disease: a narrative review. | Negroiu CE et al. | — | 2024 | → |
| The role of KLF2 in regulating hepatic lipogenesis and blood cholesterol homeostasis via the SCAP/SREBP pathway. | Huang Y et al. | — | 2024 | → |
| The Role of SCAP/SREBP as Central Regulators of Lipid Metabolism in Hepatic Steatosis. | Chandrasekaran P et al. | — | 2024 | → |
| The Role of Triglycerides in Atherosclerosis: Recent Pathophysiologic Insights and Therapeutic Implications. | Akivis Y et al. | — | 2024 | → |
| The roles of type 2 diabetes and obesity in disease activity and progression of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis. | Shinde S et al. | — | 2024 | → |
| This Is What Metabolic Dysfunction-Associated Steatotic Liver Disease Looks Like: Potential of a Multiparametric MRI Protocol. | Fischer AM et al. | — | 2024 | → |
| Tracers and Imaging of Fatty Acid and Energy Metabolism of Human Adipose Tissues. | Carpentier AC | — | 2024 | → |
| Treatment with a new barbituric acid derivative suppresses diet-induced metabolic dysfunction and non-alcoholic fatty liver disease in mice. | Suk FM et al. | — | 2024 | → |
| Type 1 diabetes mellitus and non-alcoholic fatty liver disease: a two-sample Mendelian randomization study. | Tuo L et al. | — | 2024 | → |
| Unveiling global research trends and hotspots on mitochondria in NAFLD from 2000 to 2023: A bibliometric analysis. | Hu J et al. | — | 2024 | → |
| VLDL Biogenesis and Secretion: It Takes a Village. | van Zwol W et al. | — | 2024 | → |
| AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. | Rinella ME et al. | — | 2023 | → |
| Adherence to Mediterranean Diet: Any Association with NAFLD? | Barrea L et al. | — | 2023 | → |
| Advances in the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease. | Yin X et al. | — | 2023 | → |
| AMPK and the Endocrine Control of Metabolism. | Townsend LK et al. | — | 2023 | → |
| An adipocentric perspective on the development and progression of non-alcoholic fatty liver disease. | Lee E et al. | — | 2023 | → |
| Analysis of the association between dietary patterns and nonalcoholic fatty liver disease in a county in Guangxi. | Xiao S et al. | — | 2023 | → |
| An Artemisia scoparia extract attenuates glucocorticoid-induced lipolysis in adipocytes. | Harvey I et al. | — | 2023 | → |
| A novel regulatory facet for hypertriglyceridemia: The role of microRNAs in the regulation of triglyceride-rich lipoprotein biosynthesis. | Khalifeh M et al. | — | 2023 | → |
| An update: is there a relationship between <i>H. pylori</i> infection and nonalcoholic fatty liver disease? why is this subject of interest? | Chen X et al. | — | 2023 | → |
| Aquaporin-8 ameliorates hepatic steatosis through farnesoid X receptor in obese mice. | Xiang M et al. | — | 2023 | → |
| Association between Impaired Ketogenesis and Metabolic-Associated Fatty Liver Disease. | Bae J et al. | — | 2023 | → |
| Association between Liver MRI Proton Density Fat Fraction and Liver Disease Risk. | Xia T et al. | — | 2023 | → |
| Association of body fat and muscle tissue parameters with fatty liver disease identified by ultrasound. | Song X et al. | — | 2023 | → |
| Associations between abdominal obesity indices and pathological features of non-alcoholic fatty liver disease: Chinese visceral adiposity index. | Li R et al. | — | 2023 | → |
| Bempedoic acid for nonalcoholic fatty liver disease: evidence and mechanisms of action. | Roglans N et al. | — | 2023 | → |
| Challenges and opportunities in NASH drug development. | Harrison SA et al. | — | 2023 | → |
| Characterization of an <i>in vitro</i> steatosis model simulating activated <i>de novo</i> lipogenesis in MAFLD patients. | Kim W et al. | — | 2023 | → |
| Chlorogenic Acid from Burdock Roots Ameliorates Oleic Acid-Induced Steatosis in HepG2 Cells through AMPK/ACC/CPT-1 Pathway. | Ma K et al. | — | 2023 | → |
| Cholesterol Exacerbates the Pathophysiology of Non-Alcoholic Steatohepatitis by Upregulating Hypoxia-Inducible Factor 1 and Modulating Microcirculatory Dysfunction. | Pereira ENGDS et al. | — | 2023 | → |
| Combination of an ACLY inhibitor with a GLP-1R agonist exerts additive benefits on nonalcoholic steatohepatitis and hepatic fibrosis in mice. | Desjardins EM et al. | — | 2023 | → |
| Correlation between CT Abdominal Anthropometric Measurements and Liver Density in Individuals with Non-Alcoholic Fatty Liver Disease. | Cucoranu DC et al. | — | 2023 | → |
| Cross-tissue omics analysis discovers ten adipose genes encoding secreted proteins in obesity-related non-alcoholic fatty liver disease. | Darci-Maher N et al. | — | 2023 | → |
| Current Therapeutical Approaches Targeting Lipid Metabolism in NAFLD. | Vitulo M et al. | — | 2023 | → |
| Current Treatment Options, Including Diet, Exercise, and Medications: The Impact on Histology. | Noureddin M et al. | — | 2023 | → |
| Detrimental role of SIX1 in hepatic lipogenesis and fibrosis of non-alcoholic fatty liver disease. | Gao X et al. | — | 2023 | → |
| Development of a novel human triculture model of non-alcoholic fatty liver disease and identification of berberine as ameliorating steatosis, oxidative stress and fibrosis. | Rafiei H et al. | — | 2023 | → |
| Dietary and nutrition considerations in caring for patients with nonalcoholic fatty liver disease: Updates for the practicing clinician. | Newberry C et al. | — | 2023 | → |
| Dietary pattern and hepatic lipid metabolism. | Zou P et al. | — | 2023 | → |
| Dietary Patterns, Foods, and Nutrients to Ameliorate Non-Alcoholic Fatty Liver Disease: A Scoping Review. | Montemayor S et al. | — | 2023 | → |
| Dietary Regulation of Hepatic Triacylglycerol Content-the Role of Eucaloric Carbohydrate Restriction with Fat or Protein Replacement. | Lundsgaard AM et al. | — | 2023 | → |
| Diet-induced gut dysbiosis and inflammation: Key drivers of obesity-driven NASH. | Kang GG et al. | — | 2023 | → |
| Differential Effect of Fructose in the Presence or Absence of Fatty Acids on Circadian Metabolism in Hepatocytes. | Tsameret S et al. | — | 2023 | → |
| Does the Mediterranean Diet Have Any Effect on Lipid Profile, Central Obesity and Liver Enzymes in Non-Alcoholic Fatty Liver Disease (NAFLD) Subjects? A Systematic Review and Meta-Analysis of Randomized Control Trials. | Del Bo' C et al. | — | 2023 | → |
| Dysregulation of Lipid and Glucose Metabolism in Nonalcoholic Fatty Liver Disease. | Bhat N et al. | — | 2023 | → |
| Editorial: Diabetes and non-alcoholic fatty liver disease: points of physiological and mechanistic intersection and current co-therapeutic approaches. | Giannoukakis N et al. | — | 2023 | → |
| Effects of Aramchol in patients with nonalcoholic fatty liver disease (NAFLD). A systematic review and meta-analysis. | Malik A et al. | — | 2023 | → |
| Effects of Hydroxycitric Acid Supplementation on Body Composition, Obesity Indices, Appetite, Leptin, and Adiponectin of Women with NAFLD on a Calorie-Restricted Diet. | Tutunchi H et al. | — | 2023 | → |
| Effects of Nutritionally Induced Obesity on Metabolic Pathways of Zebrafish. | Li X et al. | — | 2023 | → |
| Effects of polystyrene nanoplastic gestational exposure on mice. | Wang X et al. | — | 2023 | → |
| Effects on Diabetic Mice of Consuming Lipid Extracted from Foxtail Millet (<i>Setaria italica</i>): Gut Microbiota Analysis and Serum Metabolomics. | Wang H et al. | — | 2023 | → |
| Engineered human hepatocyte organoids enable CRISPR-based target discovery and drug screening for steatosis. | Hendriks D et al. | — | 2023 | → |
| Ethanol and its Nonoxidative Metabolites Promote Acute Liver Injury by Inducing ER Stress, Adipocyte Death, and Lipolysis. | Park SH et al. | — | 2023 | → |
| Exercise in the Management of Metabolic-Associated Fatty Liver Disease (MAFLD) in Adults: A Position Statement from Exercise and Sport Science Australia. | Keating SE et al. | — | 2023 | → |
| Feeding of fish oil and medium-chain triglycerides to canines impacts circulating structural and energetic lipids, endocannabinoids, and non-lipid metabolite profiles. | Jackson MI et al. | — | 2023 | → |
| Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat. | Lawitz EJ et al. | — | 2023 | → |
| From NAFLD to MAFLD: Definition, Pathophysiological Basis and Cardiovascular Implications. | Boccatonda A et al. | — | 2023 | → |
| From Non-Alcoholic Fatty Liver to Hepatocellular Carcinoma: A Story of (Mal)Adapted Mitochondria. | Amorim R et al. | — | 2023 | → |
| Frontiers and hotspots of adipose tissue and NAFLD: a bibliometric analysis from 2002 to 2022. | Gu S et al. | — | 2023 | → |
| Fructose drives de novo lipogenesis affecting metabolic health. | Geidl-Flueck B et al. | — | 2023 | → |
| Fructose impairs fat oxidation: Implications for the mechanism of western diet-induced NAFLD. | Inci MK et al. | — | 2023 | → |
| Fumigaclavine C ameliorates liver steatosis by attenuating hepatic de novo lipogenesis via modulation of the RhoA/ROCK signaling pathway. | Yu W et al. | — | 2023 | → |
| Gene Polymorphisms and Biological Effects of Vitamin D Receptor on Nonalcoholic Fatty Liver Disease Development and Progression. | Tourkochristou E et al. | — | 2023 | → |
| Glucocorticoids contribute to metabolic and liver impairments induced by lactation overnutrition in male adult rats. | de Souza CF et al. | — | 2023 | → |
| Glucokinase regulatory protein: a balancing act between glucose and lipid metabolism in NAFLD. | Zhang Z et al. | — | 2023 | → |
| Glycyrrhizic acid glycosides reduces extensive tripterygium glycosides-induced lipid deposition in hepatocytes. | Yang Y et al. | — | 2023 | → |
| GPR119 activation by DA-1241 alleviates hepatic and systemic inflammation in MASH mice through inhibition of NFκB signaling. | Lee SH et al. | — | 2023 | → |
| Growth hormone and nonalcoholic fatty liver disease. | Ma IL et al. | — | 2023 | → |
| Gut insulin action protects from hepatocarcinogenesis in diabetic mice comorbid with nonalcoholic steatohepatitis. | Soeda K et al. | — | 2023 | → |
| Hepatocyte FBXW7-dependent activity of nutrient-sensing nuclear receptors controls systemic energy homeostasis and NASH progression in male mice. | Xia H et al. | — | 2023 | → |
| Hepatocyte leukotriene B4 receptor 1 promotes NAFLD development in obesity. | Liu X et al. | — | 2023 | → |
| High-density lipoproteins and non-alcoholic fatty liver disease. | Hoekstra M et al. | — | 2023 | → |
| High fat diet and PCSK9 knockout modulates lipid profile of the liver and changes the expression of lipid homeostasis related genes. | Németh K et al. | — | 2023 | → |
| Host Microbiomes Influence the Effects of Diet on Inflammation and Cancer. | Mahmood R et al. | — | 2023 | → |
| Human Milk Fatty Acid Composition and Its Effect on Preterm Infants' Growth Velocity. | Ahmed B et al. | — | 2023 | → |
| Icariin Alleviates Nonalcoholic Fatty Liver Disease in Polycystic Ovary Syndrome by Improving Liver Fatty Acid Oxidation and Inhibiting Lipid Accumulation. | Hai Y et al. | — | 2023 | → |
| Identification of heat shock protein family A member 5 (HSPA5) targets involved in nonalcoholic fatty liver disease. | Rehati A et al. | — | 2023 | → |
| In-depth analysis of <i>de novo</i> lipogenesis in non-alcoholic fatty liver disease: Mechanism and pharmacological interventions. | Zhu Z et al. | — | 2023 | → |
| Inhibition of VEGF-B signaling prevents non-alcoholic fatty liver disease development by targeting lipolysis in the white adipose tissue. | Falkevall A et al. | — | 2023 | → |
| Insulin Regulation of Hepatic Lipid Homeostasis. | Uehara K et al. | — | 2023 | → |
| Insulin resistance and adipose tissue interactions as the cornerstone of metabolic (dysfunction)-associated fatty liver disease pathogenesis. | Pal SC et al. | — | 2023 | → |
| Insulin resistance in adipose tissue and metabolic diseases. | Imi Y et al. | — | 2023 | → |
| Integrated omics analysis for characterization of the contribution of high fructose corn syrup to non-alcoholic fatty liver disease in obesity. | Papadopoulos G et al. | — | 2023 | → |
| Intermittent Fasting Attenuates Metabolic-Dysfunction-Associated Steatohepatitis by Enhancing the Hepatic Autophagy-Lysosome Pathway. | Kim KE et al. | — | 2023 | → |
| Intestinal Reg4 deficiency confers susceptibility to high-fat diet-induced liver steatosis by increasing intestinal fat absorption in mice. | Wang Y et al. | — | 2023 | → |
| Intravascular hemolysis triggers NAFLD characterized by a deregulation of lipid metabolism and lipophagy blockade. | Rayego-Mateos S et al. | — | 2023 | → |
| In Vivo Hepatic Triglyceride Secretion Rate in Antisense Oligonucleotide (ASO)-Treated Mice. | Gomez-Santos B et al. | — | 2023 | → |
| Involvement of Lipophagy and Chaperone-Mediated Autophagy in the Pathogenesis of Non-Alcoholic Fatty Liver Disease by Regulation of Lipid Droplets. | Mastoridou EM et al. | — | 2023 | → |
| <i>Schisandra</i> lignans ameliorate nonalcoholic steatohepatitis by regulating aberrant metabolism of phosphatidylethanolamines. | Xue L et al. | — | 2023 | → |
| Isotope Labeling and Biochemical Assessment of Liver-Triacylglycerol in Patients with Different Levels of Histologically-Graded Liver Disease. | Syed-Abdul MM et al. | — | 2023 | → |
| Lipid droplet biogenesis and functions in health and disease. | Zadoorian A et al. | — | 2023 | → |
| Lipid Metabolism in Metabolic-Associated Steatotic Liver Disease (MASLD). | Syed-Abdul MM | — | 2023 | → |
| Lipidomics in pathogenesis, progression and treatment of nonalcoholic steatohepatitis (NASH): Recent advances. | Musso G et al. | — | 2023 | → |
| Liver fat as risk factor of hepatic and cardiometabolic diseases. | Demir M et al. | — | 2023 | → |
| Liver insulinization as a driver of triglyceride dysmetabolism. | Cook JR et al. | — | 2023 | → |
| Liver Lipidomics Analysis Revealed the Novel Ameliorative Mechanisms of L-Carnitine on High-Fat Diet-Induced NAFLD Mice. | Sun C et al. | — | 2023 | → |
| Liver saturated fat content associates with hepatic DNA methylation in obese individuals. | Sehgal R et al. | — | 2023 | → |
| Long noncoding RNA <i>lnc_217</i> regulates hepatic lipid metabolism by modulating lipogenesis and fatty acid oxidation. | Yuan X et al. | — | 2023 | → |
| Long-term treatment with the mPXR agonist PCN promotes hepatomegaly and lipid accumulation without hepatocyte proliferation in mice. | Zhang YF et al. | — | 2023 | → |
| Low-Carbohydrate Ketogenic Diet for Improvement of Glycemic Control: Mechanism of Action of Ketosis and Beneficial Effects. | Sakr HF et al. | — | 2023 | → |
| Mapping transcriptional heterogeneity and metabolic networks in fatty livers at single-cell resolution. | Coassolo L et al. | — | 2023 | → |
| Mechanisms of Lipid Droplet Accumulation in Steatotic Liver Diseases. | Dempsey JL et al. | — | 2023 | → |
| Metabolic Role of Autophagy in the Pathogenesis and Development of NAFLD. | An L et al. | — | 2023 | → |
| Metabolism as a New Avenue for Hepatocellular Carcinoma Therapy. | Gnocchi D et al. | — | 2023 | → |
| Metabolomic analysis reveals the metabolic disturbance in aortic dissection: Subtype difference and accurate diagnosis. | Zhang J et al. | — | 2023 | → |
| Metabolomic analysis shows dysregulation in amino acid and NAD+ metabolism in palmitate treated hepatocytes and plasma of non-alcoholic fatty liver disease spectrum. | Aggarwal S et al. | — | 2023 | → |
| Methodological advancements in organ-specific ectopic lipid quantitative characterization: Effects of high fat diet on muscle and liver intracellular lipids. | Grepper D et al. | — | 2023 | → |
| MiR-192-5p Ameliorates Hepatic Lipid Metabolism in Non-Alcoholic Fatty Liver Disease by Targeting <i>Yy1</i>. | Ma L et al. | — | 2023 | → |
| Mitochondrial heterogeneity in diseases. | Chen L et al. | — | 2023 | → |
| Mitochondrial metabolic dysfunction and non-alcoholic fatty liver disease: new insights from pathogenic mechanisms to clinically targeted therapy. | Zheng Y et al. | — | 2023 | → |
| Mitochondrial pyruvate carrier 1 regulates fatty acid synthase lactylation and mediates treatment of nonalcoholic fatty liver disease. | Gao R et al. | — | 2023 | → |
| Molecular and cellular mechanisms underlying the hepatoprotective role of ghrelin against NAFLD progression. | Tuero C et al. | — | 2023 | → |
| Molecular Aspects of MAFLD-New Insights on Pathogenesis and Treatment. | Filipovic B et al. | — | 2023 | → |
| Molecular Drug Simulation and Experimental Validation of the CD36 Receptor Competitively Binding to Long-Chain Fatty Acids by 7-Ketocholesteryl-9-carboxynonanoate. | Fu C et al. | — | 2023 | → |
| NAFLD-Related HCC: Focus on the Latest Relevant Preclinical Models. | Fang J et al. | — | 2023 | → |
| Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease Cross Talk. | Nysather J et al. | — | 2023 | → |
| Non-Alcoholic Fatty Liver Disease and Liver Fibrosis in Persons with Type 2 Diabetes Mellitus in Ghana: A Study of Prevalence, Severity, and Contributing Factors Using Transient Elastography. | Wiafe YA et al. | — | 2023 | → |
| Nonalcoholic Fatty Liver Disease and Omega-3 Fatty Acids: Mechanisms and Clinical Use. | Spooner MH et al. | — | 2023 | → |
| Non-Alcoholic Fatty Liver Disease, Atherosclerosis, and Cardiovascular Disease in Asia. | Lim Y et al. | — | 2023 | → |
| Nonalcoholic Fatty Liver Disease in Lean/Nonobese and Obese Individuals: A Comprehensive Review on Prevalence, Pathogenesis, Clinical Outcomes, and Treatment. | Patel AH et al. | — | 2023 | → |
| Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes and Chronic Kidney Disease. | Adrian T et al. | — | 2023 | → |
| Non-alcoholic fatty liver disease is characterised by a reduced polyunsaturated fatty acid transport via free fatty acids and high-density lipoproteins (HDL). | Mocciaro G et al. | — | 2023 | → |
| Non-alcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes, and Non-viral Hepatocarcinoma: Pathophysiological Mechanisms and New Therapeutic Strategies. | Vetrano E et al. | — | 2023 | → |
| Noninvasive tests for nonalcoholic fatty liver disease in a multi-ethnic population: The HELIUS study. | van Dijk AM et al. | — | 2023 | → |
| Non-Parenchymal Cells and the Extracellular Matrix in Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease. | van Son KC et al. | — | 2023 | → |
| Novel approach using [<sup>18</sup>F]FTHA-PET and de novo synthesized VLDL for assessment of FFA metabolism in a rat model of diet induced NAFLD. | Ustsinau U et al. | — | 2023 | → |
| Nutrigenetic Interaction Between Apolipoprotein C3 Polymorphism and Fat Intake in People with Nonalcoholic Fatty Liver Disease. | Yamamoto R et al. | — | 2023 | → |
| Nutritional regulation of hepatic de novo lipogenesis in humans. | Cross E et al. | — | 2023 | → |
| Obesity, diabetes mellitus, and cardiometabolic risk: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2023. | Bays HE et al. | — | 2023 | → |
| Offspring NAFLD liver phospholipid profiles are differentially programmed by maternal high-fat diet and maternal one carbon supplement. | Peng H et al. | — | 2023 | → |
| Olfactomedin 4 deletion exacerbates nonalcoholic fatty liver disease through P62-dependent mitophagy in mice. | Chen S et al. | — | 2023 | → |
| Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis. | Lee KC et al. | — | 2023 | → |
| Persistent fasting lipogenesis links impaired ketogenesis with citrate synthesis in humans with nonalcoholic fatty liver. | Fu X et al. | — | 2023 | → |
| Pharmacotherapies of NAFLD: updated opportunities based on metabolic intervention. | Shao Y et al. | — | 2023 | → |
| Plasma lipidomic profiling reveals metabolic adaptations to pregnancy and signatures of cardiometabolic risk: a preconception and longitudinal cohort study. | Chen L et al. | — | 2023 | → |
| Pomegranate (Punica granatum L.) peel extract ameliorates metabolic syndrome risk factors in patients with non-alcoholic fatty liver disease: a randomized double-blind clinical trial. | Barghchi H et al. | — | 2023 | → |
| PPAR-γ signaling in nonalcoholic fatty liver disease: Pathogenesis and therapeutic targets. | Chen H et al. | — | 2023 | → |
| Prevalence and Influence Factors for Non-Alcoholic Fatty Liver Disease in Long-Term Hospitalized Patients with Schizophrenia: A Cross-Sectional Retrospective Study. | Li X et al. | — | 2023 | → |
| Preventive and therapeutic effects of natural products and herbal extracts on nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. | Cao Y et al. | — | 2023 | → |
| Probiotic Yogurt Alleviates High-Fat Diet-Induced Lipid Accumulation and Insulin Resistance in Mice via the Adiponectin Pathway. | Tang C et al. | — | 2023 | → |
| Prognostication in NAFLD: physiological bases, clinical indicators, and newer biomarkers. | Terracciani F et al. | — | 2023 | → |
| Programmed cell death and lipid metabolism of macrophages in NAFLD. | Xiao Z et al. | — | 2023 | → |
| Raspberry ketone ameliorates nonalcoholic fatty liver disease in rats by activating the AMPK pathway. | Askar ME et al. | — | 2023 | → |
| Red Wine High-Molecular-Weight Polyphenolic Complex Ameliorates High-Fat Diet-Induced Metabolic Dysregulation and Perturbation in Gut Microbiota in Mice. | Suo H et al. | — | 2023 | → |
| Relationship between NAFLD and coronary artery disease: A Mendelian randomization study. | Ren Z et al. | — | 2023 | → |
| Relative Recovery of Non-Alcoholic Fatty Liver Disease (NAFLD) in Diet-Induced Obese Rats. | Aboujassoum HM et al. | — | 2023 | → |
| Replacing Foods with a High-Glycemic Index and High in Saturated Fat by Alternatives with a Low Glycemic Index and Low Saturated Fat Reduces Hepatic Fat, Even in Isocaloric and Macronutrient Matched Conditions. | Basset-Sagarminaga J et al. | — | 2023 | → |
| Resveratrol and Dulaglutide ameliorate adiposity and liver dysfunction in rats with diet-induced metabolic syndrome: Role of SIRT-1 / adipokines / PPARγ and IGF-1. | Shamardl HAMA et al. | — | 2023 | → |
| Resveratrol intervention attenuates chylomicron secretion via repressing intestinal FXR-induced expression of scavenger receptor SR-B1. | Pang J et al. | — | 2023 | → |
| Retinoic Acid Signaling in Fatty Liver Disease. | Bawa FNC et al. | — | 2023 | → |
| Role of Oxidative Stress and Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 in Nonalcoholic Fatty Liver Disease. | Memaj P et al. | — | 2023 | → |
| Sema7A protects against high-fat diet-induced obesity and hepatic steatosis by regulating adipo/lipogenesis. | Lu Q et al. | — | 2023 | → |
| Serum sex hormone-binding globulin is a mediator of the association between intrahepatic lipid content and type 2 diabetes: the Maastricht Study. | Simons PIHG et al. | — | 2023 | → |
| Severe hypertriglyceridemia: Existing and emerging therapies. | Malick WA et al. | — | 2023 | → |
| Sex differences in the association between adipose insulin resistance and non-alcoholic fatty liver disease in Chinese adults. | Wei Y et al. | — | 2023 | → |
| Single-cell transcriptomics stratifies organoid models of metabolic dysfunction-associated steatotic liver disease. | Hess A et al. | — | 2023 | → |
| Single ethanol binge causes severe liver injury in mice fed Western diet. | Yeh YT et al. | — | 2023 | → |
| SREBP Regulation of Lipid Metabolism in Liver Disease, and Therapeutic Strategies. | Li N et al. | — | 2023 | → |
| Tcf7l2 in hepatocytes regulates de novo lipogenesis in diet-induced non-alcoholic fatty liver disease in mice. | Lee DS et al. | — | 2023 | → |
| The Different Mechanisms of Lipid Accumulation in Hepatocytes Induced by Oleic Acid/Palmitic Acid and High-Fat Diet. | Zhang M et al. | — | 2023 | → |
| The Effect of Adjuvant Therapy with Molecular Hydrogen on Endogenous Coenzyme Q<sub>10</sub> Levels and Platelet Mitochondrial Bioenergetics in Patients with Non-Alcoholic Fatty Liver Disease. | Sumbalová Z et al. | — | 2023 | → |
| The Effect of Bioactive Aliment Compounds and Micronutrients on Non-Alcoholic Fatty Liver Disease. | Munteanu C et al. | — | 2023 | → |
| The effect of <i>G0S2</i> on insulin sensitivity: A proteomic analysis in a <i>G0S2</i>-overexpressed high-fat diet mouse model. | Wu D et al. | — | 2023 | → |
| The Impact and Burden of Dietary Sugars on the Liver. | Huneault HE et al. | — | 2023 | → |
| The interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease. | Finney AC et al. | — | 2023 | → |
| The Lasting Effects of COVID-19 on the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). | Backer S et al. | — | 2023 | → |
| The promising roles of medicinal plants and bioactive compounds on hepatic lipid metabolism in the treatment of non-alcoholic fatty liver disease in animal models: molecular targets. | Zakaria Z et al. | — | 2023 | → |
| Therapeutic Potentials of Reducing Liver Fat in Non-Alcoholic Fatty Liver Disease: Close Association with Type 2 Diabetes. | Tsamos G et al. | — | 2023 | → |
| Thermoneutral housing promotes hepatic steatosis in standard diet-fed C57BL/6N mice, with a less pronounced effect on NAFLD progression upon high-fat feeding. | Horakova O et al. | — | 2023 | → |
| The role of ChREBP in carbohydrate sensing and NAFLD development. | Régnier M et al. | — | 2023 | → |
| The role of hepatokines in NAFLD. | Stefan N et al. | — | 2023 | → |
| The role of hypoxia-inducible factor 1α in hepatic lipid metabolism. | Luo M et al. | — | 2023 | → |
| The vascular endothelial growth factor system-a new player in the pathogenesis and development of metabolic dysfunction-associated steatotic liver disease. | Grønbæk H et al. | — | 2023 | → |
| Thwarting Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) with Common Bean: Dose- and Sex-Dependent Protection against Hepatic Steatosis. | Lutsiv T et al. | — | 2023 | → |
| Tracking the Metabolic Fate of Exogenous Arachidonic Acid in Ferroptosis Using Dual-Isotope Labeling Lipidomics. | Reimers N et al. | — | 2023 | → |
| Translational characterization of the temporal dynamics of metabolic dysfunctions in liver, adipose tissue and the gut during diet-induced NASH development in Ldlr-/-.Leiden mice. | Gart E et al. | — | 2023 | → |
| Triglyceride glucose-waist circumference: the optimum index to screen nonalcoholic fatty liver disease in non-obese adults. | Li S et al. | — | 2023 | → |
| Ufmylation on UFBP1 alleviates non-alcoholic fatty liver disease by modulating hepatic endoplasmic reticulum stress. | Mao Z et al. | — | 2023 | → |
| Uncarboxylated Osteocalcin Decreases SCD1 by Activating AMPK to Alleviate Hepatocyte Lipid Accumulation. | Wang D et al. | — | 2023 | → |
| Understanding NAFLD: From Case Identification to Interventions, Outcomes, and Future Perspectives. | Clayton-Chubb D et al. | — | 2023 | → |
| Unmasking the enigma of lipid metabolism in metabolic dysfunction-associated steatotic liver disease: from mechanism to the clinic. | Rao G et al. | — | 2023 | → |
| Untargeted metabolomics reveals dynamic changes in metabolic profiles of rat supraspinatus tendon at three different time points after diabetes induction. | Xu K et al. | — | 2023 | → |
| We are what we eat: The role of lipids in metabolic diseases. | Berná G et al. | — | 2023 | → |
| What do we know about nutrient-based strategies targeting molecular mechanisms associated with obesity-related fatty liver disease? | Rivera-Iñiguez I et al. | — | 2023 | → |
| A biologically based model to quantitatively assess the role of the nuclear receptors liver X (LXR), and pregnane X (PXR) on chemically induced hepatic steatosis. | Bay C et al. | — | 2022 | → |
| Ablation of sphingosine kinase 2 suppresses fatty liver-associated hepatocellular carcinoma via downregulation of ceramide transfer protein. | Liu XT et al. | — | 2022 | → |
| A Combined Supplement of Probiotic Strains AP-32, bv-77, and CP-9 Increased <i>Akkermansia mucinphila</i> and Reduced Non-Esterified Fatty Acids and Energy Metabolism in HFD-Induced Obese Rats. | Liao CA et al. | — | 2022 | → |
| A comprehensive review on phytochemicals for fatty liver: are they potential adjuvants? | do Moinho TM et al. | — | 2022 | → |
| Activation of Liver mTORC1 Protects Against NASH via Dual Regulation of VLDL-TAG Secretion and De Novo Lipogenesis. | Uehara K et al. | — | 2022 | → |
| Acute intermittent hypoxia drives hepatic <i>de novo</i> lipogenesis in humans and rodents. | Hazlehurst JM et al. | — | 2022 | → |
| Adenosine-rich extract of Ganoderma lucidum: A safe and effective lipid-lowering substance. | Li H et al. | — | 2022 | → |
| A diet-induced murine model for non-alcoholic fatty liver disease with obesity and insulin resistance that rapidly develops steatohepatitis and fibrosis. | Sakuma T et al. | — | 2022 | → |
| Adipose-specific VDR Deletion Leads to Hepatic Steatosis in Female Mice Fed a Low-Fat Diet. | Tao T et al. | — | 2022 | → |
| A Lard and Soybean Oil Mixture Alleviates Low-Fat-High-Carbohydrate Diet-Induced Nonalcoholic Fatty Liver Disease in Mice. | Yan S et al. | — | 2022 | → |
| Alisol B Alleviates Hepatocyte Lipid Accumulation and Lipotoxicity via Regulating RARα-PPARγ-CD36 Cascade and Attenuates Non-Alcoholic Steatohepatitis in Mice. | Zhao Z et al. | — | 2022 | → |
| Alterations of Lipid Profile in Livers with Impaired Lipophagy. | Jonas W et al. | — | 2022 | → |
| Altered Liver Metabolism, Mitochondrial Function, Oxidative Status, and Inflammatory Response in Intrauterine Growth Restriction Piglets with Different Growth Patterns before Weaning. | Wang J et al. | — | 2022 | → |
| Antisense-mediated senseful regulation of orchestrated metabolic response. | Ozcan U | — | 2022 | → |
| A potential link between plasma short-chain fatty acids, TNF-α level and disease progression in non-alcoholic fatty liver disease: A retrospective study. | Xiong J et al. | — | 2022 | → |
| Applications of Quantitative Systems Pharmacology (QSP) in Drug Development for NAFLD and NASH and Its Regulatory Application. | Siler SQ | — | 2022 | → |
| A Prediction Model of the Incidence of Nonalcoholic Fatty Liver Disease With Visceral Fatty Obesity: A General Population-Based Study. | Zhou Y et al. | — | 2022 | → |
| Are isothiocyanates and polyphenols from <i>Brassicaceae</i> vegetables emerging as preventive/therapeutic strategies for NAFLD? The landscape of recent preclinical findings. | Bacil GP et al. | — | 2022 | → |
| Association between de novo lipogenesis susceptibility genes and coronary artery disease. | Simons PIHG et al. | — | 2022 | → |
| Association between Mediterranean Diet and Fatty Liver in Women with Overweight and Obesity. | Leone A et al. | — | 2022 | → |
| Associations of Plasma Fatty Acid Patterns During Pregnancy With Gestational Diabetes Mellitus. | Li P et al. | — | 2022 | → |
| Barley Sprout Water Extract and Saponarin Mitigate Triacylglycerol Accumulation in 3T3-L1 Adipocytes. | Kim HJ et al. | — | 2022 | → |
| CD36 promotes de novo lipogenesis in hepatocytes through INSIG2-dependent SREBP1 processing. | Zeng H et al. | — | 2022 | → |
| Celecoxib attenuates hepatosteatosis by impairing de novo lipogenesis via Akt-dependent lipogenic pathway. | Zhang C et al. | — | 2022 | → |
| Ceramide de novo synthesis in non-alcoholic fatty liver disease: Pathogenic mechanisms and therapeutic perspectives. | Yu XD et al. | — | 2022 | → |
| Characterization of diet based nonalcoholic fatty liver disease/nonalcoholic steatohepatitis in rodent models: Histological and biochemical outcomes. | Akbari G et al. | — | 2022 | → |
| Chia seeds and chemical-elicited sprouts supplementation ameliorates insulin resistance, dyslipidemia, and hepatic steatosis in obese rats. | Gómez-Velázquez HDJ et al. | — | 2022 | → |
| Chlorogenic acid improves anti-lipogenic activity of metformin by positive regulating of AMPK signaling in HepG2 cells. | Namvarjah F et al. | — | 2022 | → |
| Combinations of an acetyl CoA carboxylase inhibitor with hepatic lipid modulating agents do not augment antifibrotic efficacy in preclinical models of NASH and fibrosis. | Vijayakumar A et al. | — | 2022 | → |
| Combination Therapies for Nonalcoholic Fatty Liver Disease. | Makri ES et al. | — | 2022 | → |
| Comparison of the Lipidomic Signature of Fatty Liver in Children and Adults: A Cross-Sectional Study. | Mann JP et al. | — | 2022 | → |
| Complex regulation of fatty liver disease. | Ginsberg HN et al. | — | 2022 | → |
| Complex roles of nicotinamide N-methyltransferase in cancer progression. | Wang W et al. | — | 2022 | → |
| Comprehensive metabolite quantitative assay based on alternate metabolomics and lipidomics analyses. | Lv W et al. | — | 2022 | → |
| Crosstalk between dietary patterns, obesity and nonalcoholic fatty liver disease. | Ristic-Medic D et al. | — | 2022 | → |
| Current insights in molecular characterization of non-alcoholic fatty liver disease and treatment. | Che W et al. | — | 2022 | → |
| CYP450 drug inducibility in NAFLD via an in vitro hepatic model: Understanding drug-drug interactions in the fatty liver. | Rey-Bedon C et al. | — | 2022 | → |
| Deciphering the role of aberrant DNA methylation in NAFLD and NASH. | Vachher M et al. | — | 2022 | → |
| Deficiency of WTAP in hepatocytes induces lipoatrophy and non-alcoholic steatohepatitis (NASH). | Li X et al. | — | 2022 | → |
| De novo lipogenesis in non-alcoholic fatty liver disease: Quantification with stable isotope tracers. | Belew GD et al. | — | 2022 | → |
| Detailed Molecular Mechanisms Involved in Drug-Induced Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: An Update. | Di Pasqua LG et al. | — | 2022 | → |
| D-<i>chiro</i>-Inositol facilitates adiponectin biosynthesis and activates the AMPKα/PPARs pathway to inhibit high-fat diet-induced obesity and liver lipid deposition. | Yang Q et al. | — | 2022 | → |
| Dietary carbohydrate restriction augments weight loss-induced improvements in glycaemic control and liver fat in individuals with type 2 diabetes: a randomised controlled trial. | Thomsen MN et al. | — | 2022 | → |
| Diet, lipids, and antitumor immunity. | Prendeville H et al. | — | 2022 | → |
| Differences in Insulin Sensitivity, Secretion, and the Metabolic Clearance Rate of Glucose in Newly Diagnosed Type 2 Diabetes Mellitus Patients: The Influences of Body Mass Index and Fatty Liver. | Xie Y et al. | — | 2022 | → |
| Diosgenin Ameliorated Type II Diabetes-Associated Nonalcoholic Fatty Liver Disease through Inhibiting De Novo Lipogenesis and Improving Fatty Acid Oxidation and Mitochondrial Function in Rats. | Zhong Y et al. | — | 2022 | → |
| Discovery of 5,7-Dimethoxy-2-(3,4,5-trimethoxyphenoxy)-chromen-4-one with Lipid Lowering Effects in Hepatocytes. | Chang YH et al. | — | 2022 | → |
| Docosahexaenoic Acid Attenuates the Progression of Nonalcoholic Steatohepatitis by Suppressing the Adipocyte Inflammation via the G Protein-Coupled Receptor 120/Free Fatty Acid Receptor 4 Pathway. | Nakamoto K et al. | — | 2022 | → |
| Dual roles of B lymphocytes in mouse models of diet-induced nonalcoholic fatty liver disease. | Karl M et al. | — | 2022 | → |
| Dyrk1b promotes hepatic lipogenesis by bypassing canonical insulin signaling and directly activating mTORC2 in mice. | Bhat N et al. | — | 2022 | → |
| Dysbiosis of human microbiome and infectious diseases. | Gupta A et al. | — | 2022 | → |
| Dysregulation of hepatic metabolism with obesity: factors influencing glucose and lipid metabolism. | Nagarajan SR et al. | — | 2022 | → |
| Effect of Aerobic Exercise on Lipid Metabolism in Rats With NAFLD. | Zhou T et al. | — | 2022 | → |
| Effect of quercetin and Abelmoschus esculentus (L.) Moench on lipids metabolism and blood glucose through AMPK-α in diabetic rats (HFD/STZ). | Nasrollahi Z et al. | — | 2022 | → |
| Effects of a 12-week whole-grain or refined wheat intervention on plasma acylcarnitines, bile acids and signaling lipids, and association with liver fat: A <i>post-hoc</i> metabolomics study of a randomized controlled trial. | Gijbels A et al. | — | 2022 | → |
| Effects of Isocaloric Fructose Restriction on Ceramide Levels in Children with Obesity and Cardiometabolic Risk: Relation to Hepatic De Novo Lipogenesis and Insulin Sensitivity. | Olson E et al. | — | 2022 | → |
| Effects of long-term childhood exercise and detraining on lipid accumulation in metabolic-related organs. | Nguyen ST et al. | — | 2022 | → |
| Effects of Orlistat or Telmisartan on the Serum Free Fatty Acids in Non-alcoholic Fatty Liver Disease Patients: An Open-Labeled Randomized Controlled Study. | Wasta Esmail VA et al. | — | 2022 | → |
| Elevated de novo lipogenesis, slow liver triglyceride turnover, and clinical correlations in nonalcoholic steatohepatitis patients. | Lawitz EJ et al. | — | 2022 | → |
| Elevated Serum Regulator of Calcineurin 2 is Associated With an Increased Risk of Non-Alcoholic Fatty Liver Disease. | Fang X et al. | — | 2022 | → |
| Emerging degrader technologies engaging lysosomal pathways. | Ding Y et al. | — | 2022 | → |
| Emerging Role of Hepatic Ketogenesis in Fatty Liver Disease. | Mooli RGR et al. | — | 2022 | → |
| Endoplasmic reticulum stress in nonalcoholic (metabolic associated) fatty liver disease (NAFLD/MAFLD). | Flessa CM et al. | — | 2022 | → |
| Evolutionary and Association Analysis of Buffalo FABP Family Genes Reveal Their Potential Role in Milk Performance. | Ye T et al. | — | 2022 | → |
| Farnesoid X Receptor Deficiency Induces Hepatic Lipid and Glucose Metabolism Disorder via Regulation of Pyruvate Dehydrogenase Kinase 4. | Deng W et al. | — | 2022 | → |
| FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models. | O'Farrell M et al. | — | 2022 | → |
| Fatty Acids and Eicosanoids Change during High-Fiber Diet in NAFLD Patients-Randomized Control Trials (RCT). | Maciejewska-Markiewicz D et al. | — | 2022 | → |
| FGF9 Alleviates the Fatty Liver Phenotype by Regulating Hepatic Lipid Metabolism. | Zhao F et al. | — | 2022 | → |
| Glycohemoglobin: A new warning strategy for non-alcoholic fatty liver disease: Study from the NHANES 2017- 2020. | Hou J et al. | — | 2022 | → |
| Growth Hormone and Insulin-Like Growth Factor 1 Regulation of Nonalcoholic Fatty Liver Disease. | Dichtel LE et al. | — | 2022 | → |
| Gryllus bimaculatus De Geer hydrolysates alleviate lipid accumulation, inflammation, and endoplasmic reticulum stress in palmitic acid-treated human hepatoma G2 cells. | Kim N et al. | — | 2022 | → |
| Gut microbiome and non-alcoholic fatty liver disease. | Purohit A et al. | — | 2022 | → |
| Hawthorn or semen cassiae-alleviated high-fat diet-induced hepatic steatosis in rats <i>via</i> the reduction of endoplasmic reticulum stress. | Mao K et al. | — | 2022 | → |
| Helminth infection and helminth-derived products: A novel therapeutic option for non-alcoholic fatty liver disease. | Liu X et al. | — | 2022 | → |
| Hepatic deficiency of selenoprotein S exacerbates hepatic steatosis and insulin resistance. | Qiao L et al. | — | 2022 | → |
| Hepatic retinaldehyde dehydrogenases are modulated by tocopherol supplementation in mice with hepatic steatosis. | D'Espessailles A et al. | — | 2022 | → |
| Hepatic transcriptome profiling reveals early signatures associated with disease transition from non-alcoholic steatosis to steatohepatitis. | Magee N et al. | — | 2022 | → |
| Hepatocyte-specific deletion of adipose triglyceride lipase (adipose triglyceride lipase/patatin-like phospholipase domain containing 2) ameliorates dietary induced steatohepatitis in mice. | Fuchs CD et al. | — | 2022 | → |
| Hesperidin attenuates hepatic lipid accumulation in mice fed high-fat diet and oleic acid induced HepG2 via AMPK activation. | Chen H et al. | — | 2022 | → |
| Heterogeneity of non-alcoholic fatty liver disease (NAFLD): Implication for cardiovascular risk stratification. | Baratta F et al. | — | 2022 | → |
| Histone acetyltransferase NAA40 modulates acetyl-CoA levels and lipid synthesis. | Charidemou E et al. | — | 2022 | → |
| Hmgcs2-mediated ketogenesis modulates high-fat diet-induced hepatosteatosis. | Asif S et al. | — | 2022 | → |
| <i>In vitro</i> models for non-alcoholic fatty liver disease: Emerging platforms and their applications. | Ramos MJ et al. | — | 2022 | → |
| Immune cell-mediated features of non-alcoholic steatohepatitis. | Huby T et al. | — | 2022 | → |
| Impact of Dietary Palmitic Acid on Lipid Metabolism. | Murru E et al. | — | 2022 | → |
| Impact of NAFLD and its pharmacotherapy on lipid profile and CVD. | Wang Z et al. | — | 2022 | → |
| Improved diabetes control, allowing insulin cessation, after direct acting antiviral treatment (DAAT) of hepatitis C. | Surendran A et al. | — | 2022 | → |
| Inflammation in obesity, diabetes, and related disorders. | Rohm TV et al. | — | 2022 | → |
| Influence of NAFLD and bariatric surgery on hepatic and adipose tissue mitochondrial biogenesis and respiration. | Pedersen JS et al. | — | 2022 | → |
| Inhibiting SCAP/SREBP exacerbates liver injury and carcinogenesis in murine nonalcoholic steatohepatitis. | Kawamura S et al. | — | 2022 | → |
| Inhibition of fat accumulation, lipid dysmetabolism, cardiac inflammation, and improved nitric oxide signalling mediate the protective effects of lycopene against cardio-metabolic disorder in obese female rats. | Ugwor EI et al. | — | 2022 | → |
| Inhibition of Fatty Acid Translocase (FAT/CD36) Palmitoylation Enhances Hepatic Fatty Acid β-Oxidation by Increasing Its Localization to Mitochondria and Interaction with Long-Chain Acyl-CoA Synthetase 1. | Zeng S et al. | — | 2022 | → |
| Inhibition of nonalcoholic fatty liver disease in mice by selective inhibition of mTORC1. | Gosis BS et al. | — | 2022 | → |
| Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease. | Negi CK et al. | — | 2022 | → |
| Insulin: The master regulator of glucose metabolism. | Norton L et al. | — | 2022 | → |
| Integrative study of diet-induced mouse models of NAFLD identifies PPARα as a sexually dimorphic drug target. | Smati S et al. | — | 2022 | → |
| Interaction effect between NAFLD severity and high carbohydrate diet on gut microbiome alteration and hepatic <i>de novo</i> lipogenesis. | Kang H et al. | — | 2022 | → |
| <i>Salvia miltiorrhiza</i> Bge. (Danshen) in the Treating Non-alcoholic Fatty Liver Disease Based on the Regulator of Metabolic Targets. | Liu J et al. | — | 2022 | → |
| <i>Slc7a8</i> Deletion Is Protective against Diet-Induced Obesity and Attenuates Lipid Accumulation in Multiple Organs. | Pitere RR et al. | — | 2022 | → |
| Lactation alters the relationship between liver lipid synthesis and hepatic fat stores in the postpartum period. | Ramos-Roman MA et al. | — | 2022 | → |
| Leptin increases hepatic triglyceride export via a vagal mechanism in humans. | Metz M et al. | — | 2022 | → |
| Linking liver metabolic and vascular disease via bile acid signaling. | Fiorucci S et al. | — | 2022 | → |
| Lipid alterations in chronic liver disease and liver cancer. | Paul B et al. | — | 2022 | → |
| Lipotoxicity as the Leading Cause of Non-Alcoholic Steatohepatitis. | Branković M et al. | — | 2022 | → |
| Long non-coding RNA in Non-alcoholic fatty liver disease. | Rohilla S et al. | — | 2022 | → |
| Lotus (<i>Nelumbo nucifera</i> Gaertn.) Leaf-Fermentation Supernatant Inhibits Adipogenesis in 3T3-L1 Preadipocytes and Suppresses Obesity in High-Fat Diet-Induced Obese Rats. | He Y et al. | — | 2022 | → |
| Low fat diet versus low carbohydrate diet for management of non-alcohol fatty liver disease: A systematic review. | Varkaneh HK et al. | — | 2022 | → |
| Luteolin loaded on zinc oxide nanoparticles ameliorates non-alcoholic fatty liver disease associated with insulin resistance in diabetic rats <i>via</i> regulation of PI3K/AKT/FoxO1 pathway. | Ahmed ES et al. | — | 2022 | → |
| MD2 deficiency prevents high-fat diet-induced AMPK suppression and lipid accumulation through regulating TBK1 in non-alcoholic fatty liver disease. | Luo W et al. | — | 2022 | → |
| Mechanisms of Gynostemma pentaphyllum against non-alcoholic fibre liver disease based on network pharmacology and molecular docking. | Wang C et al. | — | 2022 | → |
| Metabolic implications of pancreatic fat accumulation. | Wagner R et al. | — | 2022 | → |
| Metabolic Injury of Hepatocytes Promotes Progression of NAFLD and AALD. | Carvalho-Gontijo R et al. | — | 2022 | → |
| Metabolic surgery. | Shikora SA et al. | — | 2022 | → |
| Metabolic Syndrome Ameliorated by 4-Methylesculetin by Reducing Hepatic Lipid Accumulation. | Li L et al. | — | 2022 | → |
| Metabolism of Triglyceride-Rich Lipoproteins. | Borén J et al. | — | 2022 | → |
| Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia. | Borén J et al. | — | 2022 | → |
| Metabolomic signature: one step forward in the process of obtaining NAFLD patients' metabolic identity card. | Lonardo A | — | 2022 | → |
| MGAT2 inhibitor decreases liver fibrosis and inflammation in murine NASH models and reduces body weight in human adults with obesity. | Cheng D et al. | — | 2022 | → |
| Mineralocorticoid receptors in non-alcoholic fatty liver disease. | Schreier B et al. | — | 2022 | → |
| Mitochondria homeostasis: Biology and involvement in hepatic steatosis to NASH. | Li YF et al. | — | 2022 | → |
| Mitochondrial Dysfunction Plays Central Role in Nonalcoholic Fatty Liver Disease. | Ramanathan R et al. | — | 2022 | → |
| Mitochondrial respiration is decreased in visceral but not subcutaneous adipose tissue in obese individuals with fatty liver disease. | Pafili K et al. | — | 2022 | → |
| Mitochondria, oxidative stress and nonalcoholic fatty liver disease: A complex relationship. | Karkucinska-Wieckowska A et al. | — | 2022 | → |
| Modulation of Dyslipidemia Markers Apo B/Apo A and Triglycerides/HDL-Cholesterol Ratios by Low-Carbohydrate High-Fat Diet in a Rat Model of Metabolic Syndrome. | Alnami A et al. | — | 2022 | → |
| Molecular Advances in MAFLD-A Link between Sphingolipids and Extracellular Matrix in Development and Progression to Fibrosis. | Kołakowski A et al. | — | 2022 | → |
| Molecular mechanism and therapeutic significance of dihydromyricetin in nonalcoholic fatty liver disease. | Gong H et al. | — | 2022 | → |
| MRG15 aggravates non-alcoholic steatohepatitis progression by regulating the mitochondrial proteolytic degradation of TUFM. | Tian C et al. | — | 2022 | → |
| NAFLD: Mechanisms, Treatments, and Biomarkers. | Nassir F | — | 2022 | → |
| New Insights of OLFM2 and OLFM4 in Gut-Liver Axis and Their Potential Involvement in Nonalcoholic Fatty Liver Disease. | Bertran L et al. | — | 2022 | → |
| Non-alcoholic Fatty Liver Disease and Steatohepatitis: Risk Factors and Pathophysiology. | Akter S | — | 2022 | → |
| Nonalcoholic Fatty Liver Disease in Children with Obesity: Narrative Review and Research Gaps. | Furthner D et al. | — | 2022 | → |
| Non-Alcoholic Fatty Liver Disease (NAFLD) Pathogenesis and Natural Products for Prevention and Treatment. | Guo X et al. | — | 2022 | → |
| Nonalcoholic Steatohepatitis (NASH) and Atherosclerosis: Explaining Their Pathophysiology, Association and the Role of Incretin-Based Drugs. | Galatou E et al. | — | 2022 | → |
| Non-Invasive Approaches to Estimate Liver Steatosis and Stiffness in Children With Non-Alcoholic Fatty Liver Disease. | Yodoshi T et al. | — | 2022 | → |
| Obesity-Related Insulin Resistance: The Central Role of Adipose Tissue Dysfunction. | Mocciaro G et al. | — | 2022 | → |
| Obeticholic acid and ferrostatin-1 differentially ameliorate non-alcoholic steatohepatitis in AMLN diet-fed ob/ob mice. | Li S et al. | — | 2022 | → |
| Obeticholic acid inhibits hepatic fatty acid uptake independent of FXR in mouse. | Lin C et al. | — | 2022 | → |
| Omega-3 fatty acids and metabolic partitioning of fatty acids within the liver in the context of nonalcoholic fatty liver disease. | Calder PC | — | 2022 | → |
| Omega-3 phospholipids and obesity-associated NAFLD: Potential mechanisms and therapeutic perspectives. | Mitrovic M et al. | — | 2022 | → |
| PACAP attenuates hepatic lipid accumulation through the FAIM/AMPK/IRβ axis during overnutrition. | Luo W et al. | — | 2022 | → |
| PATAS, a First-in-Class Therapeutic Peptide Biologic, Improves Whole-Body Insulin Resistance and Associated Comorbidities In Vivo. | Schreyer E et al. | — | 2022 | → |
| Pathogenesis from Inflammation to Cancer in NASH-Derived HCC. | Yu S et al. | — | 2022 | → |
| Peroxisome Proliferator-Activated Receptor α Has a Protective Effect on Fatty Liver Caused by Excessive Sucrose Intake. | Yamazaki T et al. | — | 2022 | → |
| Perspectives in liver redox imbalance: Toxicological and pharmacological aspects underlying iron overloading, nonalcoholic fatty liver disease, and thyroid hormone action. | Videla LA et al. | — | 2022 | → |
| Plant and marine N3-PUFA regulation of fatty acid trafficking along the adipose tissue-liver axis varies according to nutritional state. | Rajna A et al. | — | 2022 | → |
| Platelets in Non-alcoholic Fatty Liver Disease. | Dalbeni A et al. | — | 2022 | → |
| Polyphenol Supplementation Did Not Affect Insulin Sensitivity and Fat Deposition During One-Month Overfeeding in Randomized Placebo-Controlled Trials in Men and in Women. | Segrestin B et al. | — | 2022 | → |
| Polysaccharides influence human health <i>via</i> microbiota-dependent and -independent pathways. | Gan L et al. | — | 2022 | → |
| Potential Therapeutic Implication of Herbal Medicine in Mitochondria-Mediated Oxidative Stress-Related Liver Diseases. | Park MN et al. | — | 2022 | → |
| PPAR Alpha as a Metabolic Modulator of the Liver: Role in the Pathogenesis of Nonalcoholic Steatohepatitis (NASH). | Todisco S et al. | — | 2022 | → |
| Predictive Risk Factors of Nonalcoholic Fatty Liver Disease in a Lean Chinese Population. | Liu L et al. | — | 2022 | → |
| Pregnancy and lactation after Roux-en-Y gastric bypass worsen nonalcoholic fatty liver disease in obese rats and lead to differential programming of hepatic <i>de novo</i> lipogenesis in offspring. | Bertasso IM et al. | — | 2022 | → |
| Puerarin ameliorates nonalcoholic fatty liver in rats by regulating hepatic lipid accumulation, oxidative stress, and inflammation. | Zhou J et al. | — | 2022 | → |
| Purendan alleviates non-alcoholic fatty liver disease in aged type 2 diabetic rats via regulating mTOR/S6K1/SREBP-1c signaling pathway. | Fan L et al. | — | 2022 | → |
| Qushi Huayu decoction attenuated hepatic lipid accumulation via JAK2/STAT3/CPT-1A-related fatty acid β-oxidation in mice with non-alcoholic steatohepatitis. | Sun Q et al. | — | 2022 | → |
| Rats with high aerobic capacity display enhanced transcriptional adaptability and upregulation of bile acid metabolism in response to an acute high-fat diet. | Stierwalt HD et al. | — | 2022 | → |
| Rebuttal to: Inflammation: The Straw That Broke the NAFLD Liver! | Mooli RGR et al. | — | 2022 | → |
| Recent advances on FXR-targeting therapeutics. | Panzitt K et al. | — | 2022 | → |
| Reduction in gut-derived MUFAs via intestinal stearoyl-CoA desaturase 1 deletion drives susceptibility to NAFLD and hepatocarcinoma. | Ducheix S et al. | — | 2022 | → |
| Regular exercise combined with ferulic acid exhibits antiobesity effect and regulates metabolic profiles in high-fat diet-induced mice. | Wang O et al. | — | 2022 | → |
| Regulatory Roles of Caspase-11 Non-Canonical Inflammasome in Inflammatory Liver Diseases. | Yi YS | — | 2022 | → |
| Replication stress triggered by nucleotide pool imbalance drives DNA damage and cGAS-STING pathway activation in NAFLD. | Donne R et al. | — | 2022 | → |
| Reply. | Ren Z et al. | — | 2022 | → |
| Reprogramming of Hepatic Metabolism and Microenvironment in Nonalcoholic Steatohepatitis. | Rui L et al. | — | 2022 | → |
| Role of Lipogenesis Rewiring in Hepatocellular Carcinoma. | Zhou Y et al. | — | 2022 | → |
| Selective PPARα Modulator Pemafibrate and Sodium-Glucose Cotransporter 2 Inhibitor Tofogliflozin Combination Treatment Improved Histopathology in Experimental Mice Model of Non-Alcoholic Steatohepatitis. | Murakami K et al. | — | 2022 | → |
| Sesame Oil Ameliorates Alanine Aminotransferase, Aspartate Aminotransferase, and Fatty Liver Grade in Women with Nonalcoholic Fatty Liver Disease Undergoing Low-Calorie Diet: A Randomized Double-Blind Controlled Trial. | Atefi M et al. | — | 2022 | → |
| SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection. | Androutsakos T et al. | — | 2022 | → |
| Stearoyl-CoA desaturase 1: A potential target for non-alcoholic fatty liver disease?-perspective on emerging experimental evidence. | Jeyakumar SM et al. | — | 2022 | → |
| Synthetic Retinoids Beyond Cancer Therapy. | Gudas LJ | — | 2022 | → |
| Systemic LSD1 Inhibition Prevents Aberrant Remodeling of Metabolism in Obesity. | Ramms B et al. | — | 2022 | → |
| Targeted Lipidomics Reveal the Effects of Different Phospholipids on the Phospholipid Profiles of Hepatic Mitochondria and Endoplasmic Reticulum in High-Fat/High-Fructose-Diet-Induced Nonalcoholic Fatty Liver Disease Mice. | Zhang LY et al. | — | 2022 | → |
| Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH). | Xu X et al. | — | 2022 | → |
| Theabrownin and <i>Poria cocos</i> Polysaccharide Improve Lipid Metabolism <i>via</i> Modulation of Bile Acid and Fatty Acid Metabolism. | Wang J et al. | — | 2022 | → |
| The Coexistence of Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. | Kosmalski M et al. | — | 2022 | → |
| The effect of 12 weeks of combined training on hepatic fat content and metabolic flexibility of individuals with non-alcoholic fatty liver disease: Protocol of an open-label, single-center randomized control trial. | Huang W et al. | — | 2022 | → |
| The effect of sesame oil consumption compared to sunflower oil on lipid profile, blood pressure, and anthropometric indices in women with non-alcoholic fatty liver disease: a randomized double-blind controlled trial. | Vahedi H et al. | — | 2022 | → |
| The effects of voluntary wheel running during weight-loss on biomarkers of hepatic lipid metabolism and inflammation in C57Bl/6J mice. | Wooten JS et al. | — | 2022 | → |
| The genetic interactions between non-alcoholic fatty liver disease and cardiovascular diseases. | Chew NWS et al. | — | 2022 | → |
| The interplay of Western diet and binge drinking on the onset, progression, and outlook of liver disease. | Skinner RC et al. | — | 2022 | → |
| The ketogenic diet prevents steatosis and insulin resistance by reducing lipogenesis, diacylglycerol accumulation and protein kinase C activity in male rat liver. | Jani S et al. | — | 2022 | → |
| The ménage à trois of autophagy, lipid droplets and liver disease. | Filali-Mouncef Y et al. | — | 2022 | → |
| The metabolic triad of non-alcoholic fatty liver disease, visceral adiposity and type 2 diabetes: Implications for treatment. | Cariou B | — | 2022 | → |
| The microbial metabolome in metabolic-associated fatty liver disease. | Li M et al. | — | 2022 | → |
| Theophylline Extracted from Fu Brick Tea Affects the Metabolism of Preadipocytes and Body Fat in Mice as a Pancreatic Lipase Inhibitor. | Liu TT et al. | — | 2022 | → |
| The Pathogenesis of HCC Driven by NASH and the Preventive and Therapeutic Effects of Natural Products. | Shao G et al. | — | 2022 | → |
| The RNA binding protein human antigen R is a gatekeeper of liver homeostasis. | Subramanian P et al. | — | 2022 | → |
| The role of PCSK9 in NAFLD/NASH and therapeutic implications of PCSK9 inhibition. | Momtazi-Borojeni AA et al. | — | 2022 | → |
| The role of RNA binding proteins in hepatocellular carcinoma. | Zhang K et al. | — | 2022 | → |
| The Synergistic Protective Effect of γ-Oryzanol (OZ) and N-Acetylcysteine (NAC) against Experimentally Induced NAFLD in Rats Entails Hypoglycemic, Antioxidant, and PPARα Stimulatory Effects. | Alwadani AH et al. | — | 2022 | → |
| Tracing metabolic flux in vivo: basic model structures of tracer methodology. | Kim IY et al. | — | 2022 | → |
| Triglyceride: A mediator of the association between waist-to-height ratio and non-alcoholic fatty liver disease: A second analysis of a population-based study. | Hu H et al. | — | 2022 | → |
| Triglyceride and glucose index is a simple and easy-to-calculate marker associated with nonalcoholic fatty liver disease. | Kim KS et al. | — | 2022 | → |
| Undifferentiated Induced Pluripotent Stem Cells as a Genetic Model for Nonalcoholic Fatty Liver Disease. | Muñoz A et al. | — | 2022 | → |
| Upregulation of hepatic CD36 via glucocorticoid receptor activation contributes to dexamethasone-induced liver lipid metabolism disorder in mice. | Chen M et al. | — | 2022 | → |
| USP22 regulates lipidome accumulation by stabilizing PPARγ in hepatocellular carcinoma. | Ning Z et al. | — | 2022 | → |
| Vanadium(IV)-Chlorodipicolinate Protects against Hepatic Steatosis by Ameliorating Lipid Peroxidation, Endoplasmic Reticulum Stress, and Inflammation. | Wang Y et al. | — | 2022 | → |
| Weight Cycling Impairs Pancreatic Insulin Secretion but Does Not Perturb Whole-Body Insulin Action in Mice With Diet-Induced Obesity. | Winn NC et al. | — | 2022 | → |
| Western diet-induced mouse model of non-alcoholic fatty liver disease associated with metabolic outcomes: Features of gut microbiome-liver-adipose tissue axis. | Romualdo GR et al. | — | 2022 | → |
| When Sugar Reaches the Liver: Phenotypes of Patients with Diabetes and NAFLD. | Rojano-Toimil A et al. | — | 2022 | → |
| (Wh)olistic (E)ndocannabinoidome-Microbiome-Axis Modulation through (N)utrition (WHEN) to Curb Obesity and Related Disorders. | Sihag J et al. | — | 2022 | → |
| Why does obesity cause diabetes? | Klein S et al. | — | 2022 | → |
| Xiaoyao San attenuates hepatic steatosis through estrogen receptor α pathway in ovariectomized ApoE-/- mice. | Hu T et al. | — | 2022 | → |
| 100<sup>th</sup> anniversary of the discovery of insulin perspective: insulin and adipose tissue fatty acid metabolism. | Carpentier AC | — | 2021 | → |
| 6-Gingerol Ameliorates Hepatic Steatosis via HNF4α/miR-467b-3p/GPAT1 Cascade. | Ahn J et al. | — | 2021 | → |
| A comprehensive review of long non-coding RNAs in the pathogenesis and development of non-alcoholic fatty liver disease. | Shabgah AG et al. | — | 2021 | → |
| Adaptive and maladaptive roles for ChREBP in the liver and pancreatic islets. | Katz LS et al. | — | 2021 | → |
| Adipose Insulin Resistance and Decreased Adiponectin Are Correlated With Metabolic Abnormalities in Nonobese Men. | Kiya M et al. | — | 2021 | → |
| Alaska backcountry expeditionary hunting promotes rapid improvements in metabolic biomarkers in healthy males and females. | Coker MS et al. | — | 2021 | → |
| An Analysis of the Potential Relationship of Triglyceride Glucose and Body Mass Index With Stroke Prognosis. | Hou Z et al. | — | 2021 | → |
| A Narrative Review on the Role of AMPK on De Novo Lipogenesis in Non-Alcoholic Fatty Liver Disease: Evidence from Human Studies. | von Loeffelholz C et al. | — | 2021 | → |
| An Emerging Facet of Diabetes Mellitus: The Nexus of Gastrointestinal Disorders. | Modi S et al. | — | 2021 | → |
| A network-based approach reveals the dysregulated transcriptional regulation in non-alcoholic fatty liver disease. | Yang H et al. | — | 2021 | → |
| A novel chicken model of fatty liver disease induced by high cholesterol and low choline diets. | Lin CW et al. | — | 2021 | → |
| A novel, multitargeted endogenous metabolic modulator composition impacts metabolism, inflammation, and fibrosis in nonalcoholic steatohepatitis-relevant primary human cell models. | Daou N et al. | — | 2021 | → |
| A rapid juvenile murine model of nonalcoholic steatohepatitis (NASH): Chronic intermittent hypoxia exacerbates Western diet-induced NASH. | Zhou J et al. | — | 2021 | → |
| A retinoic acid receptor β2 agonist attenuates transcriptome and metabolome changes underlying nonalcohol-associated fatty liver disease. | Tang XH et al. | — | 2021 | → |
| A review of non-alcoholic fatty liver disease in non-obese and lean individuals. | Ahadi M et al. | — | 2021 | → |
| A Scoping Review on Lipocalin-2 and Its Role in Non-Alcoholic Steatohepatitis and Hepatocellular Carcinoma. | Krizanac M et al. | — | 2021 | → |
| Association between consumption of edible seaweeds and newly diagnosed non-alcohol fatty liver disease: The TCLSIH Cohort Study. | Li H et al. | — | 2021 | → |
| Association between the Frequency of Daily Toothbrushing and Development of Nonalcoholic Fatty Liver Disease. | Yamamoto K et al. | — | 2021 | → |
| A Systems Approach Dissociates Fructose-Induced Liver Triglyceride from Hypertriglyceridemia and Hyperinsulinemia in Male Mice. | Doridot L et al. | — | 2021 | → |
| Autonomic Imbalance Increases the Risk for Non-alcoholic Fatty Liver Disease. | Jung I et al. | — | 2021 | → |
| Basic science to clinical trials in non-alcoholic fatty liver disease and alcohol-related liver disease: collaboration with industry. | Asgharpour A et al. | — | 2021 | → |
| Beneficial Effects of Tamarind Trypsin Inhibitor in Chitosan-Whey Protein Nanoparticles on Hepatic Injury Induced High Glycemic Index Diet: A Preclinical Study. | Aguiar AJFC et al. | — | 2021 | → |
| Beverages and Non-alcoholic fatty liver disease (NAFLD): Think before you drink. | Chhimwal J et al. | — | 2021 | → |
| Beyond the X Factor: Relevance of Sex Hormones in NAFLD Pathophysiology. | Della Torre S | — | 2021 | → |
| Bile acid activated receptors: Integrating immune and metabolic regulation in non-alcoholic fatty liver disease. | Biagioli M et al. | — | 2021 | → |
| <b>β</b><sub>2</sub>-Adrenergic receptor agonist induced hepatic steatosis in mice: modeling nonalcoholic fatty liver disease in hyperadrenergic states. | Shi Y et al. | — | 2021 | → |
| Clinical relevance of lipid panel and aminotransferases in the context of hepatic steatosis and fibrosis as measured by transient elastography (FibroScan®). | Chi-Cervera LA et al. | — | 2021 | → |
| Comparison of Ketogenic Diets with and without Ketone Salts versus a Low-Fat Diet: Liver Fat Responses in Overweight Adults. | Crabtree CD et al. | — | 2021 | → |
| Comparison of the Improvement Effect of Deep Ocean Water with Different Mineral Composition on the High Fat Diet-Induced Blood Lipid and Nonalcoholic Fatty Liver Disease in a Mouse Model. | Lee CY et al. | — | 2021 | → |
| Concerted regulation of non-alcoholic fatty liver disease progression by microRNAs in apolipoprotein E-deficient mice. | López-Pastor AR et al. | — | 2021 | → |
| Contrasting Effects of Fasting on Liver-Adipose Axis in Alcohol-Associated and Non-alcoholic Fatty Liver. | Rasineni K et al. | — | 2021 | → |
| Co-option of PPARα in the regulation of lipogenesis and fatty acid oxidation in CLA-induced hepatic steatosis. | Cai D et al. | — | 2021 | → |
| Cordycepin Ameliorates Nonalcoholic Steatohepatitis by Activation of the AMP-Activated Protein Kinase Signaling Pathway. | Lan T et al. | — | 2021 | → |
| Coronavirus disease 2019 severity in obesity: Metabolic dysfunction-associated fatty liver disease in the spotlight. | Vasques-Monteiro IML et al. | — | 2021 | → |
| Degradation of lipid droplets by chimeric autophagy-tethering compounds. | Fu Y et al. | — | 2021 | → |
| Dietary carbohydrates and fats in nonalcoholic fatty liver disease. | Yki-Järvinen H et al. | — | 2021 | → |
| Dietary Fats, Serum Cholesterol and Liver Cancer Risk: A Systematic Review and Meta-Analysis of Prospective Studies. | Zhao L et al. | — | 2021 | → |
| Dietary Macronutrient Composition Differentially Modulates the Remodeling of Mitochondrial Oxidative Metabolism during NAFLD. | Kattapuram N et al. | — | 2021 | → |
| Dietary sugar restriction reduces hepatic de novo lipogenesis in boys with fatty liver disease. | Chung ST et al. | — | 2021 | → |
| DietSee: An on-hand, portable, strip-type biosensor for lipolysis monitoring via real-time amperometric determination of glycerol in blood. | Degrelle SA et al. | — | 2021 | → |
| Direct and indirect control of hepatic glucose production by insulin. | Lewis GF et al. | — | 2021 | → |
| Does a high intake of green leafy vegetables protect from NAFLD? Evidence from a large population study. | Li H et al. | — | 2021 | → |
| Ectopic fat in liver and skeletal muscle is associated with shorter overall survival in patients with colorectal liver metastases. | van Dijk DPJ et al. | — | 2021 | → |
| Effect of Curcumin Nanoemulsions Stabilized with MAG and DAG-MCFAs in a Fructose-Induced Hepatic Steatosis Rat Model. | Agame-Lagunes B et al. | — | 2021 | → |
| Effect of recombinant human growth hormone on liver fat content in young adults with nonalcoholic fatty liver disease. | Pan CS et al. | — | 2021 | → |
| Effects of Micronutrient Supplementation on Glucose and Hepatic Lipid Metabolism in a Rat Model of Diet Induced Obesity. | Khatiwada S et al. | — | 2021 | → |
| Elevated serum S14 levels are associated with more severe liver steatosis by ultrasonography. | Lin WT et al. | — | 2021 | → |
| Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. | Ferguson D et al. | — | 2021 | → |
| Endoplasmic Reticulum Stress and Autophagy in the Pathogenesis of Non-alcoholic Fatty Liver Disease (NAFLD): Current Evidence and Perspectives. | Flessa CM et al. | — | 2021 | → |
| Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease. | Makri E et al. | — | 2021 | → |
| Ethnicity-specific alterations of plasma and hepatic lipidomic profiles are related to high NAFLD rate and severity in Hispanic Americans, a pilot study. | Mazi TA et al. | — | 2021 | → |
| Evaluating causality of cellular senescence in non-alcoholic fatty liver disease. | Meijnikman AS et al. | — | 2021 | → |
| Exercise prevents fatty liver by modifying the compensatory response of mitochondrial metabolism to excess substrate availability. | Hoene M et al. | — | 2021 | → |
| Exposure to High-Fat Style Diet Induced Renal and Liver Structural Changes, Lipid Accumulation and Inflammation in Intact and Ovariectomized Female Rats. | Sucedaram Y et al. | — | 2021 | → |
| Fatty acids may influence insulin dynamics through modulation of albumin-Zn<sup>2+</sup> interactions. | Arya S et al. | — | 2021 | → |
| Fatty Acid Synthase-Suppressor Screening Identifies Sorting Nexin 8 as a Therapeutic Target for NAFLD. | Hu Y et al. | — | 2021 | → |
| Fenofibrate Regulates Visceral Obesity and Nonalcoholic Steatohepatitis in Obese Female Ovariectomized C57BL/6J Mice. | Shin Y et al. | — | 2021 | → |
| Gene-Environmental Interactions as Metabolic Drivers of Nonalcoholic Steatohepatitis. | Albhaisi S et al. | — | 2021 | → |
| Genetic Contribution to Non-alcoholic Fatty Liver Disease and Prognostic Implications. | Martin K et al. | — | 2021 | → |
| Genetic predisposition similarities between NASH and ASH: Identification of new therapeutic targets. | Bianco C et al. | — | 2021 | → |
| Geniposide and Chlorogenic Acid Combination Improves Non-Alcoholic Fatty Liver Disease Involving the Potent Suppression of Elevated Hepatic SCD-1. | Chen C et al. | — | 2021 | → |
| Green Tea and Epigallocatechin Gallate (EGCG) for the Management of Nonalcoholic Fatty Liver Diseases (NAFLD): Insights into the Role of Oxidative Stress and Antioxidant Mechanism. | Tang G et al. | — | 2021 | → |
| Gut inflammation exacerbates high-fat diet induced steatosis by suppressing VLDL-TG secretion through HNF4α pathway. | Li P et al. | — | 2021 | → |
| Hepatic deletion of Mboat7 (LPIAT1) causes activation of SREBP-1c and fatty liver. | Xia M et al. | — | 2021 | → |
| Hepatic Insulin Resistance Is Not Pathway Selective in Humans With Nonalcoholic Fatty Liver Disease. | Ter Horst KW et al. | — | 2021 | → |
| Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis. | Ooi GJ et al. | — | 2021 | → |
| Hepatic Lipidomics Analysis Reveals the Ameliorative Effects of Highland Barley β-Glucan on Western Diet-Induced Nonalcoholic Fatty Liver Disease Mice. | Liu H et al. | — | 2021 | → |
| Hepatic Mediators of Lipid Metabolism and Ketogenesis: Focus on Fatty Liver and Diabetes. | Fernandes GW et al. | — | 2021 | → |
| Hepatopathy Associated With Type 1 Diabetes: Distinguishing Non-alcoholic Fatty Liver Disease From Glycogenic Hepatopathy. | Mertens J et al. | — | 2021 | → |
| Hepatotoxicity or hepatoprotection of emodin? Two sides of the same coin by <sup>1</sup>H-NMR metabolomics profiling. | Ruan L et al. | — | 2021 | → |
| High Fat, High Sugar Diet and DJOS Bariatric Surgery Influence Plasma Levels of Fetuin-B, Growth Differentiation Factor-15, and Pentraxin 3 in Diet-Induced Obese Sprague-Dawley Rats. | Poloczek J et al. | — | 2021 | → |
| High-throughput LC-MS method to investigate postprandial lipemia: considerations for future precision nutrition research. | Mucinski JM et al. | — | 2021 | → |
| Historical narrative from fatty liver in the nineteenth century to contemporary NAFLD - Reconciling the present with the past. | Ayonrinde OT | — | 2021 | → |
| Hormone-sensitive lipase: sixty years later. | Recazens E et al. | — | 2021 | → |
| How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease? | Geng Y et al. | — | 2021 | → |
| Human intestinal lipid storage through sequential meals reveals faster dinner appearance is associated with hyperlipidemia. | Jacome-Sosa M et al. | — | 2021 | → |
| Hypoxia-Inducible Factors as Key Players in the Pathogenesis of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis. | Holzner LMW et al. | — | 2021 | → |
| Identification of Key Genes and Immune Infiltrate in Nonalcoholic Steatohepatitis: A Bioinformatic Analysis. | Jiang ZY et al. | — | 2021 | → |
| <i>Euphausia pacifica</i> (North Pacific Krill): Review of Chemical Features and Potential Benefits of 8-HEPE against Metabolic Syndrome, Dyslipidemia, NAFLD, and Atherosclerosis. | Ishida N et al. | — | 2021 | → |
| IGFBP-2 as a biomarker in NAFLD improves hepatic steatosis: an integrated bioinformatics and experimental study. | Chen X et al. | — | 2021 | → |
| Immunological mechanisms and therapeutic targets of fatty liver diseases. | Wang H et al. | — | 2021 | → |
| Impact of Dietary Crude Protein Level on Hepatic Lipid Metabolism in Weaned Female Piglets. | Liu N et al. | — | 2021 | → |
| Improvement of Obesity and Dyslipidemic Activity of <i>Amomum tsao-ko</i> in C57BL/6 Mice Fed a High-Carbohydrate Diet. | Park JH et al. | — | 2021 | → |
| Increased Hepatic Lipogenesis Elevates Liver Cholesterol Content. | Berger JM et al. | — | 2021 | → |
| Inflammation initiates a vicious cycle between obesity and nonalcoholic fatty liver disease. | Luo Y et al. | — | 2021 | → |
| Inhibiting serotonin signaling through HTR2B in visceral adipose tissue improves obesity-related insulin resistance. | Choi WG et al. | — | 2021 | → |
| Inhibition of fatty acid synthase with FT-4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non-alcoholic fatty liver disease: Results from two early-phase randomized trials. | Beysen C et al. | — | 2021 | → |
| Insulin Resistance across the Spectrum of Nonalcoholic Fatty Liver Disease. | Armandi A et al. | — | 2021 | → |
| Insulin signaling in health and disease. | Saltiel AR | — | 2021 | → |
| Insulin treatment improves liver histopathology and decreases expression of inflammatory and fibrogenic genes in a hyperglycemic, dyslipidemic hamster model of NAFLD. | Jensen VS et al. | — | 2021 | → |
| Interplay between Heart Disease and Metabolic Steatosis: A Contemporary Perspective. | Ramadan MS et al. | — | 2021 | → |
| Intestinal Barrier and Permeability in Health, Obesity and NAFLD. | Portincasa P et al. | — | 2021 | → |
| Intestine-liver crosstalk in Type 2 Diabetes and non-alcoholic fatty liver disease. | Nawrot M et al. | — | 2021 | → |
| It Is High Time Physicians Thought of Natural Products for Alleviating NAFLD. Is There Sufficient Evidence to Use Them? | Tarantino G et al. | — | 2021 | → |
| Lipid Disorders in NAFLD and Chronic Kidney Disease. | Yang M et al. | — | 2021 | → |
| Lipodistrophy: a paradigm for understanding the consequences of "overloading" adipose tissue. | Lim K et al. | — | 2021 | → |
| Lipolysis: cellular mechanisms for lipid mobilization from fat stores. | Grabner GF et al. | — | 2021 | → |
| Lipoprotein Insulin Resistance Index Reflects Liver Fat Content in Patients With Nonalcoholic Fatty Liver Disease. | Vittal A et al. | — | 2021 | → |
| Liver fat storage pathways: methodologies and dietary effects. | Roumans KHM et al. | — | 2021 | → |
| Loss of Acot12 contributes to NAFLD independent of lipolysis of adipose tissue. | Park S et al. | — | 2021 | → |
| Maternal tadalafil therapy for fetal growth restriction prevents non-alcoholic fatty liver disease and adipocyte hypertrophy in the offspring. | Kawamura T et al. | — | 2021 | → |
| Mechanisms and disease consequences of nonalcoholic fatty liver disease. | Loomba R et al. | — | 2021 | → |
| Metabolic-associated fatty liver disease and lipoprotein metabolism. | Heeren J et al. | — | 2021 | → |
| Metabolic-associated Fatty Liver Disease as Assessed by the Fatty Liver Index Among Migrant and Non-migrant Ghanaian Populations. | van Dijk AM et al. | — | 2021 | → |
| Metabolic Changes of Hepatocytes in NAFLD. | Lu Q et al. | — | 2021 | → |
| Metabolic drivers of non-alcoholic fatty liver disease. | Bence KK et al. | — | 2021 | → |
| Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)-A Condition Associated with Heightened Sympathetic Activation. | Carnagarin R et al. | — | 2021 | → |
| Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC. | Kim H et al. | — | 2021 | → |
| Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests. | Masoodi M et al. | — | 2021 | → |
| Microbial Flavonoid Metabolism: A Cardiometabolic Disease Perspective. | Osborn LJ et al. | — | 2021 | → |
| Mitochondrial dysfunction in nonalcoholic fatty liver disease and alcohol related liver disease. | Prasun P et al. | — | 2021 | → |
| Mitochondria Matter: Systemic Aspects of Nonalcoholic Fatty Liver Disease (NAFLD) and Diagnostic Assessment of Liver Function by Stable Isotope Dynamic Breath Tests. | Di Ciaula A et al. | — | 2021 | → |
| Modelling human liver fibrosis in the context of non-alcoholic steatohepatitis using a microphysiological system. | Kostrzewski T et al. | — | 2021 | → |
| Molecular aspects of fructose metabolism and metabolic disease. | Herman MA et al. | — | 2021 | → |
| NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment. | Targher G et al. | — | 2021 | → |
| NAFLD-Related Hepatocarcinoma: The Malignant Side of Metabolic Syndrome. | Michelotti A et al. | — | 2021 | → |
| New targets for NAFLD. | Parlati L et al. | — | 2021 | → |
| Nonalcohol fatty liver disease: balancing supply and utilization of triglycerides. | Santos-Baez LS et al. | — | 2021 | → |
| Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease: A Review of Links and Risks. | Cheung A et al. | — | 2021 | → |
| Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review. | Cariou B et al. | — | 2021 | → |
| Nonalcoholic fatty liver disease, circulating ketone bodies and all-cause mortality in a general population-based cohort. | Post A et al. | — | 2021 | → |
| Non-Alcoholic Fatty Liver Disease in Lean and Non-Obese Individuals: Current and Future Challenges. | Kuchay MS et al. | — | 2021 | → |
| Non-Alcoholic Fatty Liver Disease in Obese Youth With Insulin Resistance and Type 2 Diabetes. | Scapaticci S et al. | — | 2021 | → |
| Non-Alcoholic Fatty Liver Disease Is an Independent Risk Factor for LDL Cholesterol Target Level. | Lee JH et al. | — | 2021 | → |
| Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans. | Pafili K et al. | — | 2021 | → |
| Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies? | Di Ciaula A et al. | — | 2021 | → |
| Nonalcoholic Fatty Liver Disease (NAFLD): Pathogenesis and Noninvasive Diagnosis. | Dorairaj V et al. | — | 2021 | → |
| Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity. | Tilg H et al. | — | 2021 | → |
| Non-Alcoholic Fatty Liver in Patients with Chylomicronemia. | Maltais M et al. | — | 2021 | → |
| Nonalcoholic fatty pancreas disease: An emerging clinical challenge. | Zhang CL et al. | — | 2021 | → |
| Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors. | Francque S et al. | — | 2021 | → |
| Obesity, insulin resistance and their interaction on liver enzymes. | Liu C et al. | — | 2021 | → |
| Overfeeding Saturated Fat Increases LDL (Low-Density Lipoprotein) Aggregation Susceptibility While Overfeeding Unsaturated Fat Decreases Proteoglycan-Binding of Lipoproteins. | Ruuth M et al. | — | 2021 | → |
| Pathophysiological mechanisms and clinical evidence of relationship between Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease. | Galiero R et al. | — | 2021 | → |
| Position Statement on Fat Consumption and Cardiovascular Health - 2021. | Izar MCO et al. | — | 2021 | → |
| Positive Effects of Exercise Intervention without Weight Loss and Dietary Changes in NAFLD-Related Clinical Parameters: A Systematic Review and Meta-Analysis. | Babu AF et al. | — | 2021 | → |
| PPARα agonist WY-14,643 induces adipose atrophy and fails to blunt chronic ethanol-induced hepatic fat accumulation in mice lacking adipose FGFR1. | Xu Y et al. | — | 2021 | → |
| Predictive Modeling of MAFLD Based on Hsp90α and the Therapeutic Application of Teprenone in a Diet-Induced Mouse Model. | Xie Y et al. | — | 2021 | → |
| Procyanidin B2 Alleviates Palmitic Acid-Induced Injury in HepG2 Cells via Endoplasmic Reticulum Stress Pathway. | Li YM et al. | — | 2021 | → |
| Protective Effect of <i>Cudrania tricuspidata</i> Extract against High-Fat Diet Induced Nonalcoholic Fatty Liver Disease through Nrf-2/HO-1 Pathway. | Shrestha J et al. | — | 2021 | → |
| Protective Effects of Voluntary Exercise on Hepatic Fat Accumulation Induced by Dietary Restriction in Zucker Fatty Rats. | Kurosaka Y et al. | — | 2021 | → |
| Protocols for Mitochondria as the Target of Pharmacological Therapy in the Context of Nonalcoholic Fatty Liver Disease (NAFLD). | Grattagliano I et al. | — | 2021 | → |
| PSA controls hepatic lipid metabolism by regulating the NRF2 signaling pathway. | Huang B et al. | — | 2021 | → |
| Quantitative flux analysis in mammals. | Bartman CR et al. | — | 2021 | → |
| Recent Progress in the Molecular Imaging of Nonalcoholic Fatty Liver Disease. | Wegrzyniak O et al. | — | 2021 | → |
| Regulation on Citrate Influx and Metabolism through Inhibiting SLC13A5 and ACLY: A Novel Mechanism Mediating the Therapeutic Effects of Curcumin on NAFLD. | Sun Q et al. | — | 2021 | → |
| Relationship between body composition and the histology of non-alcoholic fatty liver disease: a cross-sectional study. | Miyake T et al. | — | 2021 | → |
| Rho-Kinase as a Therapeutic Target for Nonalcoholic Fatty Liver Diseases. | Sousa-Lima I et al. | — | 2021 | → |
| Role of histone deacetylase on nonalcoholic fatty liver disease. | Fu S et al. | — | 2021 | → |
| Role of Insulin Resistance in MAFLD. | Sakurai Y et al. | — | 2021 | → |
| Role of Oxidative Stress in the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Implications for Prevention and Therapy. | Arroyave-Ospina JC et al. | — | 2021 | → |
| Roles of Ceramides in Non-Alcoholic Fatty Liver Disease. | Hajduch E et al. | — | 2021 | → |
| Roles of IκB kinases and TANK-binding kinase 1 in hepatic lipid metabolism and nonalcoholic fatty liver disease. | Huh JY et al. | — | 2021 | → |
| Serum anandamide level as a potential indicator for nonalcoholic fatty liver disease severity. | Ramadan A et al. | — | 2021 | → |
| Serum aromatic and branched-chain amino acids associated with NASH demonstrate divergent associations with serum lipids. | de Mello VD et al. | — | 2021 | → |
| Sex hormone-binding globulin: biomarker and hepatokine? | Simons PIHG et al. | — | 2021 | → |
| Sexual dimorphism in inorganic mercury toxicokinetics and the attendant lipotoxic and non-lipotoxic dyslipidemia in the rat. | Wusu AD et al. | — | 2021 | → |
| Splice variants of metabolic nuclear receptors: Relevance for metabolic disease and therapeutic targeting. | Mukha A et al. | — | 2021 | → |
| Src-mediated Tyr353 phosphorylation of IP3R1 promotes its stability and causes apoptosis in palmitic acid-treated hepatocytes. | Yu T et al. | — | 2021 | → |
| SREBP-1c and lipogenesis in the liver: an update1. | Ferré P et al. | — | 2021 | → |
| Sulforaphane Attenuates Nonalcoholic Fatty Liver Disease by Inhibiting Hepatic Steatosis and Apoptosis. | Li J et al. | — | 2021 | → |
| Suppression of insulin-induced gene 1 (INSIG1) function promotes hepatic lipid remodelling and restrains NASH progression. | Azzu V et al. | — | 2021 | → |
| Tanshinone IIA Downregulates Lipogenic Gene Expression and Attenuates Lipid Accumulation through the Modulation of LXRα/SREBP1 Pathway in HepG2 Cells. | Gao WY et al. | — | 2021 | → |
| The absence of hepatic glucose-6 phosphatase/ChREBP couple is incompatible with survival in mice. | Rajas F et al. | — | 2021 | → |
| The Association between Branched-Chain Amino Acids (BCAAs) and Cardiometabolic Risk Factors in Middle-Aged Caucasian Women Stratified According to Glycemic Status. | Kubacka J et al. | — | 2021 | → |
| The Contribution of Dietary Fructose to Non-alcoholic Fatty Liver Disease. | Yu S et al. | — | 2021 | → |
| The effect of endurance training on non-alcoholic fatty liver disease in mice. | Melo L et al. | — | 2021 | → |
| The effects of canola and olive oils consumption compared to sunflower oil, on lipid profile and hepatic steatosis in women with polycystic ovarian syndrome: a randomized controlled trial. | Yahay M et al. | — | 2021 | → |
| The Efficacy of <i>Plantago major</i> Seed on Liver Enzymes in Nonalcoholic Fatty Liver Disease: A Randomized Double-Blind Clinical Trial. | Jazayeri SF et al. | — | 2021 | → |
| The Emerging Influences of Alpha-Fetoprotein in the Tumorigenesis and Progression of Hepatocellular Carcinoma. | Xu Y et al. | — | 2021 | → |
| The interaction between the gut microbiota and dietary carbohydrates in nonalcoholic fatty liver disease. | Park G et al. | — | 2021 | → |
| The interplay between host cellular and gut microbial metabolism in NAFLD development and prevention. | Yu SY et al. | — | 2021 | → |
| The Interplay between Insulin Resistance, Inflammation, Oxidative Stress, Base Excision Repair and Metabolic Syndrome in Nonalcoholic Fatty Liver Disease. | Ziolkowska S et al. | — | 2021 | → |
| The mechanism of increased intestinal palmitic acid absorption and its impact on hepatic stellate cell activation in nonalcoholic steatohepatitis. | Hanayama M et al. | — | 2021 | → |
| The methyltransferase METTL3 negatively regulates nonalcoholic steatohepatitis (NASH) progression. | Li X et al. | — | 2021 | → |
| The potential ameliorative impacts of cerium oxide nanoparticles against fipronil-induced hepatic steatosis. | Wasef L et al. | — | 2021 | → |
| The Role of Fatty Acids in Non-Alcoholic Fatty Liver Disease Progression: An Update. | Hliwa A et al. | — | 2021 | → |
| The role of hepatic lipid composition in obesity-related metabolic disease. | Willis SA et al. | — | 2021 | → |
| The Role of Lipids, Lipid Metabolism and Ectopic Lipid Accumulation in Axon Growth, Regeneration and Repair after CNS Injury and Disease. | Roy D et al. | — | 2021 | → |
| The Role of Mitochondrial Adaptation and Metabolic Flexibility in the Pathophysiology of Obesity and Insulin Resistance: an Updated Overview. | Tsilingiris D et al. | — | 2021 | → |
| The Role of Neuropeptide Y in Adipocyte-Macrophage Crosstalk during High Fat Diet-Induced Adipose Inflammation and Liver Steatosis. | Park S et al. | — | 2021 | → |
| The Role of Notch Signaling Pathway in Non-Alcoholic Fatty Liver Disease. | Xu H et al. | — | 2021 | → |
| The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease. | Jennison E et al. | — | 2021 | → |
| The Role of the Transsulfuration Pathway in Non-Alcoholic Fatty Liver Disease. | Werge MP et al. | — | 2021 | → |
| The Tailgate Study: Differing metabolic effects of a bout of excessive eating and drinking. | Syed-Abdul MM et al. | — | 2021 | → |
| Translational insight into prothrombotic state and hypercoagulation in nonalcoholic fatty liver disease. | Ciavarella A et al. | — | 2021 | → |
| Triglyceride-lowering and anti-inflammatory mechanisms of omega-3 polyunsaturated fatty acids for atherosclerotic cardiovascular risk reduction. | Liu QK | — | 2021 | → |
| Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives. | Vallianou N et al. | — | 2021 | → |
| Uridine attenuates obesity, ameliorates hepatic lipid accumulation and modifies the gut microbiota composition in mice fed with a high-fat diet. | Liu Y et al. | — | 2021 | → |
| Val-Val-Tyr-Pro protects against non-alcoholic steatohepatitis in mice by modulating the gut microbiota and gut-liver axis activation. | Xie X et al. | — | 2021 | → |
| Vanillic Acid and Non-Alcoholic Fatty Liver Disease: A Focus on AMPK in Adipose and Liver Tissues. | Shekari S et al. | — | 2021 | → |
| β-Cell Dysfunction, Hepatic Lipid Metabolism, and Cardiovascular Health in Type 2 Diabetes: New Directions of Research and Novel Therapeutic Strategies. | Al-Mrabeh A | — | 2021 | → |
| A CD209 ligand and a sialidase inhibitor differentially modulate adipose tissue and liver macrophage populations and steatosis in mice on the Methionine and Choline-Deficient (MCD) diet. | Pilling D et al. | — | 2020 | → |
| A look to the future in non-alcoholic fatty liver disease: Are glucagon-like peptide-1 analogues or sodium-glucose co-transporter-2 inhibitors the answer? | Vincent RK et al. | — | 2020 | → |
| Angiotensin-(1-7), the product of ACE2 ameliorates NAFLD by acting through its receptor Mas to regulate hepatic mitochondrial function and glycolipid metabolism. | Song LN et al. | — | 2020 | → |
| Anti-Obesity Effect of <i>DKB-117</i> through the Inhibition of Pancreatic Lipase and <i>α-</i>Amylase Activity. | Kim DH et al. | — | 2020 | → |
| Associations between Plasma Branched Chain Amino Acids and Health Biomarkers in Response to Resistance Exercise Training Across Age. | Sayda MH et al. | — | 2020 | → |
| Chronic Inflammation in Non-Alcoholic Steatohepatitis: Molecular Mechanisms and Therapeutic Strategies. | Luci C et al. | — | 2020 | → |
| Deletion of KLF10 Leads to Stress-Induced Liver Fibrosis upon High Sucrose Feeding. | Lee J et al. | — | 2020 | → |
| Dietary Oxysterol, 7-Ketocholesterol Accelerates Hepatic Lipid Accumulation and Macrophage Infiltration in Obese Mice. | Chang J et al. | — | 2020 | → |
| Dim Light at Night Disturbs Molecular Pathways of Lipid Metabolism. | Okuliarova M et al. | — | 2020 | → |
| Dysregulated lipid metabolism links NAFLD to cardiovascular disease. | Deprince A et al. | — | 2020 | → |
| Effect of Adrenergic Agonists on High-Fat Diet-Induced Hepatic Steatosis in Mice. | Nakade Y et al. | — | 2020 | → |
| Effect of pemafibrate on fatty acid levels and liver enzymes in non-alcoholic fatty liver disease patients with dyslipidemia: A single-arm, pilot study. | Seko Y et al. | — | 2020 | → |
| Effects of TM6SF2 E167K on hepatic lipid and very low-density lipoprotein metabolism in humans. | Borén J et al. | — | 2020 | → |
| FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases. | Tillman EJ et al. | — | 2020 | → |
| Hepatic Carbohydrate Response Element Binding Protein Activation Limits Nonalcoholic Fatty Liver Disease Development in a Mouse Model for Glycogen Storage Disease Type 1a. | Lei Y et al. | — | 2020 | → |
| Hepatic Deficiency of Augmenter of Liver Regeneration Predisposes to Nonalcoholic Steatohepatitis and Fibrosis. | Kumar S et al. | — | 2020 | → |
| Hypoxia and Non-alcoholic Fatty Liver Disease. | Isaza SC et al. | — | 2020 | → |
| Inhibition of vascular adhesion protein-1 modifies hepatic steatosis <i>in vitro</i> and <i>in vivo</i>. | Shepherd EL et al. | — | 2020 | → |
| Lipidomics Analysis Indicates Disturbed Hepatocellular Lipid Metabolism in <i>Reynoutria multiflora</i>-Induced Idiosyncratic Liver Injury. | Wu X et al. | — | 2020 | → |
| MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy. | Xian YX et al. | — | 2020 | → |
| Maternal green tea extract intake during lactation attenuates hepatic lipid accumulation in adult male rats exposed to a continuous high-fat diet from the foetal period. | Yamasaki S et al. | — | 2020 | → |
| Mechanisms of muscle insulin resistance and the cross-talk with liver and adipose tissue. | da Silva Rosa SC et al. | — | 2020 | → |
| Multiple organs involved in the pathogenesis of non-alcoholic fatty liver disease. | Li X et al. | — | 2020 | → |
| N-Acetyl Cysteine Targets Hepatic Lipid Accumulation to Curb Oxidative Stress and Inflammation in NAFLD: A Comprehensive Analysis of the Literature. | Dludla PV et al. | — | 2020 | → |
| Non-alcoholic Fatty Liver Disease as a Canonical Example of Metabolic Inflammatory-Based Liver Disease Showing a Sex-Specific Prevalence: Relevance of Estrogen Signaling. | Della Torre S | — | 2020 | → |
| Non-Alcoholic Steatohepatitis: A Review of Its Mechanism, Models and Medical Treatments. | Peng C et al. | — | 2020 | → |
| Nutrients, Genetic Factors, and Their Interaction in Non-Alcoholic Fatty Liver Disease and Cardiovascular Disease. | Lombardi R et al. | — | 2020 | → |
| Obesity and Diabetes: A Sword of Damocles for Future Generations. | Angi A et al. | — | 2020 | → |
| Organismal Fructose Metabolism in Health and Non-Alcoholic Fatty Liver Disease. | Skenderian S et al. | — | 2020 | → |
| Oxidative Stress in NAFLD: Role of Nutrients and Food Contaminants. | Rives C et al. | — | 2020 | → |
| PAPPA-mediated adipose tissue remodeling mitigates insulin resistance and protects against gestational diabetes in mice and humans. | Rojas-Rodriguez R et al. | — | 2020 | → |
| Pathogenesis and pathways: nonalcoholic fatty liver disease & alcoholic liver disease. | Robinson KE et al. | — | 2020 | → |
| Pathophysiological mechanisms underlying MAFLD. | Kuchay MS et al. | — | 2020 | → |
| Physiopathology of Lifestyle Interventions in Non-Alcoholic Fatty Liver Disease (NAFLD). | Carneros D et al. | — | 2020 | → |
| Playing Jekyll and Hyde-The Dual Role of Lipids in Fatty Liver Disease. | Molenaar MR et al. | — | 2020 | → |
| Significance of Simple Steatosis: An Update on the Clinical and Molecular Evidence. | Mazzolini G et al. | — | 2020 | → |
| TANK-Binding Kinase 1 Regulates the Localization of Acyl-CoA Synthetase ACSL1 to Control Hepatic Fatty Acid Oxidation. | Huh JY et al. | — | 2020 | → |
| The effect of adiponectin in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) and the potential role of polyphenols in the modulation of adiponectin signaling. | Shabalala SC et al. | — | 2020 | → |
| The hepatic lipidome and HNF4α and SHBG expression in human liver. | Winters SJ et al. | — | 2020 | → |
| The nuclear and cytoplasmic roles of miR-320 in non-alcoholic fatty liver disease. | Zhan J et al. | — | 2020 | → |
| The Role of Lipophagy in the Development and Treatment of Non-Alcoholic Fatty Liver Disease. | Grefhorst A et al. | — | 2020 | → |
| Tri-Herbal Medicine Divya Sarva-Kalp-Kwath (Livogrit) Regulates Fatty Acid-Induced Steatosis in Human HepG2 Cells through Inhibition of Intracellular Triglycerides and Extracellular Glycerol Levels. | Balkrishna A et al. | — | 2020 | → |
| Understanding the Multiple Effects of PCBs on Lipid Metabolism. | Shan Q et al. | — | 2020 | → |
| USP7 mediates pathological hepatic de novo lipogenesis through promoting stabilization and transcription of ZNF638. | Ni W et al. | — | 2020 | → |
| Western Diet Causes Obesity-Induced Nonalcoholic Fatty Liver Disease Development by Differentially Compromising the Autophagic Response. | Simoes ICM et al. | — | 2020 | → |